Update on glaucoma

Glaucoma affects millions of people worldwide, but it is difficult to diagnose and manage.

Glaucoma is a major cause of irreversible blindness worldwide, and it also causes substantial disability before patients become blind. Glaucoma is difficult to detect and diagnose, and it is highly undertreated globally. In most surveys carried out in high-income countries, over 50% of people found to have glaucoma had not been diagnosed and are therefore not receiving treatment, rising to over 90% in low- and/or middle-income countries. This is because glaucoma is mostly asymptomatic until relatively late in the disease, so patients do not notice that there is a problem. In many low- and/or middle-income settings, as many as 35% of people diagnosed with glaucoma already have severe sight loss: they presented too late to benefit from interventions that may have preserved their vision.

Our aim in this issue of the Community Eye Health Journal is to provide practical articles that will help clinicians facing the challenge of providing care for glaucoma patients. Topics include glaucoma detection and diagnosis, gonioscopy (a vital examination technique), the latest guidelines for open-angle glaucoma management, and tips for managing neovascular glaucoma and the painful, blind eye. We also look at the importance of counselling and how low vision support can benefit patients with vision loss due to glaucoma.

Glaucoma is a huge topic, and this issue covers care for adults only, concentrating on open-angle disease. Many useful resources are listed, including an additional 10 pages of new content only available on our website and smartphone app (see back page for details).

Our first Community Eye Health Journal webinar will take place on World Glaucoma Day, 22 March 2022, featuring a number of authors who have contributed to this issue. Subscribe to our mailing list (www.cehjournal.org/subscribe) to receive the link for the webinar and updates when new articles are published online.
Defining and diagnosing glaucoma: a focus on blindness prevention

A diagnostic approach that focuses on patients with definite (or clinical) glaucoma optimises the likelihood of preventing visual disability due to this potentially blinding condition.

The term glaucoma refers to a group of diseases that affect the optic nerve and could potentially lead to irreversible visual loss. Glaucamatos optic neuropathy is the hallmark of all types of glaucoma. It is characterised by deformation of the optic nerve (see Figure 1, page 4), which manifests as diffuse or focal narrowing of the neuroretinal rim and peripapillary retinal nerve fibre layer loss. The type of glaucoma, the severity of the disease, and the risk of blindness can be assessed by carrying out gonioscopy, slit lamp examination, visual field tests, and intraocular pressure (IOP) measurement.

Definitions of glaucoma

The definition of glaucoma in adults has changed over the years due to changes in our understanding of how glaucoma affects the eye, the technology available, and the

About this issue

Glaucoma affects millions of people worldwide, but it is difficult to diagnose and manage. In this issue, we have included practical articles to help clinicians facing the challenge of providing care to glaucoma patients. Topics include glaucoma detection and diagnosis, gonioscopy (a vital examination technique), the latest guidelines for open-angle glaucoma management, and tips for managing neovascular glaucoma and the painful, blind eye. We also look at the importance of counselling and how low vision support can benefit patients with vision loss due to glaucoma.

Contents

31 Update on glaucoma
Elmien Wolvaardt and Victor H Hu
32 Defining and diagnosing glaucoma: a focus on blindness prevention
Jibran Mohamed-Noriega and G Chandra Sekhar
36 The optic nerve head in glaucoma
Rupert RA Bource and Tasneem Khatib
40 Gonioscopy skills and techniques
Winnie Nolan and Adeola Onakoya
43 Management of chronic open-angle glaucoma
Heiko Philippin
47 Counselling in a glaucoma care service
Fatima Kyari, Heiko Philippin, Peter Shah, Hannah Faal, Sani Babayo and Mohammed Abdull
51 Low vision care with glaucoma: there is more you can do!
Karín Van Dijk, Ambora Kristowsia Kimaro and Heiko Philippin
53 Neovascular glaucoma: prevention and treatment
Jibran Mohamed-Noriega and Jason A Penniecook
55 Managing the painful blind eye
Jason A Penniecook, Doris Saral Garza Cruz and Maria Soledad Pehin Caminos
57 Minimum requirements for a glaucoma programme
Fatima Kyari and Rohit C Khanna
59 Minimally invasive glaucoma surgery (MIGS) devices: risks, benefits and suitability
Francisco Otárola and Francisco Pooley
61 The global challenge of glaucoma
Victor H Hu
62 Exploring strategies for trachoma elimination in Ethiopia
Adugna Amin, Almameyhu Sisay and Tim Jesudason
63 Test your knowledge: glaucoma
64 Picture quiz and useful resources

Editor
Elmien Wolvaardt
editor@cehjournal.org

Medical editor
Victor H Hu

Consulting editor for Issue 112
Victor H Hu

Editorial administrator
Anita Shah admin@cehjournal.org

Editorial committee
Simon Arunga (Uganda)
João M Furtado (Brazil)
Clare Gilbert (UK)
Esmael Habtamu (Ethiopia)
Fatima Kyari (Nigeria)
Ciku Mathenge (Rwanda)
Nyawera Mwangi (Kenya)
GVS Murthy (India)
Heiko Philippin (Germany)
Thulsiraj Ravilla (India)
Serge Resnikoff (Geneva)
Jude Stern (Australia)

Sumrana Yasmin (Pakistan)
David Yoorton (UK)

Editorial advisors
Nick Astbury (Partnerships)
John Buchan (Ophthalmology)
Jenny Evans (Systematic reviews)
Michelle Hennelly (Ophthalmic nursing)
Islay Macaggart (Disability)
Priya Marjoria (Optometry)
Daksha Patel (Education)

Regional consultants
Hannah Faal (AFR)
Kovin Naidoo (AFR)
Van Lansingsh (AMR)
Andrea Zin (AMR)
Iain Murdoch (EUR)
Janos Nemeth (EUR)
GVS Murthy (SEAR)
R Thulsiraj (SEAR)
Abbar Qureshi (EMR)
Mansur Rubiu (EMR)
Leshan Tan (WPR)
Hugh Taylor (WPR)

Design
Lance Bellers

Printing
Newman Thomson

Download our app
Download the free Community Eye Health Journal app today: bit.ly/CEH-app

Visit us online www.cehjournal.org

Subscribe
Visit: www.cehjournal.org/subscribe
Email: web@cehjournal.org

Readers in low- and middle-income countries receive print copies free of charge. To subscribe, send your name, occupation, and postal address to:
Anita Shah, International Centre for Eye Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
Email: admin@cehjournal.org
reasons why a particular definition was constructed. A current clinical definition of glaucoma is: “A characteristic pattern of glaucomatous optic neuropathy (e.g., narrowing of the neuroretinal rim) with corresponding visual field defects.”

Other changes related to glaucoma might be present in some patients before a clinical diagnosis is made. These may include:

- Thinning of the retinal nerve fibre layer or ganglion cell layer, which can be visualised using optical coherence tomography (OCT)
- Other functional changes such as reduced contrast sensitivity and electrophysiological abnormalities.

However, if clinically significant glaucomatous damage has occurred, then optic disc changes are normally visible, and it is very unusual that glaucoma would be diagnosed from visual field or OCT changes without disc features.

In this article, we want to propose an approach to diagnosing adults with glaucoma that is focused on preventing visual disability. With this approach, we distinguish between two groups of patients:

- Patients with definite (or unequivocal) glaucoma: those who have definite signs of glaucomatous optic neuropathy. They are at imminent risk of visual loss, usually need treatment, and must be monitored.
- Patients with suspected (or equivocal) glaucoma: those with possible signs of glaucomatous optic neuropathy. They are not at immediate risk of visual loss, at least in the short term, and usually do not need treatment, but can/must be followed up and monitored (depending on the patient).

We propose that attention is focused on patients with definite glaucoma as they are at greater risk of blindness and are likely to require monitoring and treatment by more experienced eye care providers.

**Essential investigations**

The following investigations are needed in order to determine whether a patient has definite glaucoma requiring treatment, has suspected glaucoma and also for ongoing monitoring.

- **Visual acuity with best correction.** Although visual acuity only deteriorates at the last stages of glaucoma, measuring it on all visits is important to assess the overall visual function and rule-out other diseases.
- **Anterior segment examination using a slit lamp.** This will help in the detection of secondary types of glaucoma such as pseudoexfoliation, uveitic or pigmentary glaucoma.
- **Examination of the optic nerve head.** This is done using a slit lamp (binocularly) and a 90D or similar lens. Perform a dilated examination to rule out other retinal diseases and to make it easier to examine the optic nerve. Do this on the initial visit and yearly or if any clinical parameter (decreased visual acuity, new onset metamorphopsia etc.) changes significantly.
- **Visual field testing.** Carry out static, automated perimetry, commonly performed using a Humphrey visual field machine.
- **Tonometry.** Use Goldmann’s applanation tonometer.
Optional investigations
These additional investigations or tests can be performed if needed and if the equipment is available.

Measuring central corneal thickness. This can improve the accuracy of measurements using Goldmann’s applanation tonometer because this method overestimates IOP in patients with thick corneas and underestimates it in those with thin corneas. However, nomograms to ‘correct’ the IOP tend to be inaccurate at an individual level and are not recommended. A thin central cornea might influence the decision if the target IOP is reached in a patient with progressive disease, as the actual IOP is likely to be higher than measured.

Optical coherence tomography (OCT). This can help in the examination of the optic nerve and retina. The most frequently used metrics are the average thickness of the circumpapilar retinal nerve fibre and ganglion cell layer. However, each innovation cycle produces a different generation of devices with incompatible measurements, so the results cannot be compared for long-term follow-up assessments.

Corneal hysteresis. This non-contact tonometry technique also assesses the corneal biomechanical response and may prove to be helpful for glaucoma assessment.

Characteristics of definite glaucoma
After an initial or single examination
The characteristics of a definite or unequivocal diagnosis of glaucoma and/or where intervention might be needed, after an initial or single examination include:

1. Focal complete loss of the neuroretinal rim. The disc damage likelihood scale (DDLS) is a good way of grading the optic disc.¹
2. DDLS stage ≥ 6.
3. Cup-to-disc ratio > 0.8.
4. Focal narrowing of the neuroretinal rim, with a corresponding visual field defect. It is important to identify if the sector of the optic nerve that is affected corresponds to the location of the VF defect. Representations of the structure-function relationship, such as the Garway-Heath map, help clinicians identify if the damaged sector of the neuroretinal rim is affecting the corresponding visual field locations (Figure 2).
5. IOP > 35 mm Hg is not diagnostic of glaucoma, but almost all patients with this IOP level need IOP-lowering interventions. A high IOP in the absence of disc damage may be seen in patients with a secondary glaucoma or primary angle closure disease. Over-estimation of the IOP should be considered, e.g., a non-contact tonometer used or a very thick cornea. It is recommended to repeat the measurement before initiating treatment.

Figure 1 Different forms of glaucomatous optic neuropathy. A Enlarged CDR. B Focal superior disc rim narrowing. C Diffuse loss of the inferior disc rim. D Inferotemporal thinning of the disc rim and retinal nerve fibre layer defect.
After consecutive examinations
On follow-up examination, the following signs of progression would confirm an unequivocal or definite diagnosis of glaucoma:

1. Progression of a visual field defect that corresponds to a location of narrow neuroretinal rim or retinal nerve fibre layer loss.

2. Progression of glaucomatous optic neuropathy:
   - Enlargement of the vertical cup-disc ratio > 0.2
   - Increase in DDLS > 2 stages
   - Increased narrowing of the neuroretinal rim (change in a sector of the neuroretinal rim (NNR) from narrow to complete loss or from a homogeneous neuroretinal rim to a narrow sector)
   - Significant expansion of a retinal nerve fibre layer defect on OCT
   - Change in the course of vessels due to changes of the optic nerve head
   - The detection of a single new disc haemorrhage usually should not be considered sufficient to diagnose glaucoma or progression, however, they do increase the risk of developing glaucoma and visual field deterioration, particularly if they appear repeatedly.

There are other factors which need to be considered when deciding on and planning the treatment of a person with glaucoma.

Patients with confirmed glaucoma, i.e., those who are most in need of treatment, can be diagnosed using a slit lamp, tonometer and visual fields alone. Clinicians who do not have access to other instruments, such as OCT, can be reassured that their patients are receiving good care so long as they receive a good clinical examination and visual field analysis.

When to suspect glaucoma
The identification of only one of the following characteristics is not enough to confirm the diagnosis of glaucoma, but they do raise the suspicion of possible glaucoma. See Figure 1 for examples.

- Cup-to-disc ratio > 0.7 (this value applies to all disc sizes, but in small discs, a smaller cup-to-disc ratio represents greater damage than in larger discs)
- Diffuse narrowing of the neuroretinal rim
- DDLS stage ≥ 4
- Disc haemorrhages
- Retinal nerve fibre layer defects
- IOP > 24 mm Hg increases the risk for glaucoma, especially in thin corneas
- Abnormal visual field defects (remember that all the diseases that affect the visual pathway from dry eye affecting the cornea, cataracts affecting the lens, retinal changes, to cerebral strokes affecting the posterior visual pathway, can affect the visual field results)
- A reduction in the thickness of OCT parameters.

It is important to remember that an OCT scan that flags in red the thickness of the retinal nerve fibre layer, ganglion cell layer, or optic nerve head rim of a patient is not enough to diagnose glaucoma. These parameters are compared to a normative dataset that underrepresent many ethnic and age groups. Similarly, an OCT scan with all parameters in green is not enough to rule out glaucomatous optic neuropathy and should not be considered equivalent to a ‘normal’ optic nerve. OCT changes which, in reality, represent early glaucomatous changes, typically involve only the superior or infero-temporal neuroretinal rim or macular ganglion cell layer. These changes should usually correspond with optic disc changes seen clinically and/or with visual field changes (Figure 2).

It is always important to exclude non-glaucomatous causes of an enlarged cup-to-disc ratio and loss of neuroretinal rim or retinal nerve fibre layers.

Glaucoma classification
After clinical or definite glaucoma is diagnosed, the two main questions for the clinician are:

1. Is this glaucoma primary or secondary?
   It is important to rule out secondary glaucomas which might well carry a high risk of glaucoma blindness. These include those which could have causative treatment if identified appropriately (e.g., neovascular glaucoma) and those associated with medical conditions (e.g., uveitic or increased episcleral pressure glaucoma) and which may even potentially be life threatening (e.g., rheumatological diseases and cavernous-carotid fistulas).

2. Is the anterior chamber angle open or closed?
   Gonioscopy is critical.

The management plan of a patient with glaucoma differs significantly depending on whether the iridotrabecular angle (where aqueous drains out of the eye) is open, narrow or closed and it is vitally important to determine this with gonioscopy.

When a patient is diagnosed with definite glaucoma, it is the responsibility of all eye care providers to advise patients and family about the increased risk of glaucoma in first-degree relatives.

References
2 Bitos D, Heijl A and Bengtsson B. Integration and fusion of standard automated perimetry and optical coherence tomography data for improved automated glaucoma diagnostics. BMC Ophthalmol 2011;11(20).

Further reading
The optic nerve head in glaucoma

All types of glaucoma involve glaucomatous optic neuropathy. The key to detection and management of glaucoma is understanding how to examine the optic nerve head (ONH).

This article addresses the following issues:

- How to examine the ONH
- Normal characteristics of the ONH
- Characteristics of a glaucomatous ONH
- How to tell if the glaucomatous optic neuropathy is getting worse.

The ONH can be examined using a direct ophthalmoscope, an indirect ophthalmoscope, or a posterior pole lens with a slit lamp (Figure 1).

Many types of health professional can assess the ONH accurately after having appropriate training. Dilating the pupil makes this easier and will improve the accuracy of the examination, regardless of which instrument is used.

Where the equipment is available, more sophisticated techniques such as ocular coherence tomography can also be used to complement the clinical examination of the ONH and provide quantitative measurements.

The time available to view the ONH is often short as the examination is uncomfortable for the patient. It is therefore essential that the examiner has a strategy for making the observations needed to distinguish a glaucomatous ONH from a normal ONH.

Before you start, you should first be able to recognise the characteristics of both a normal and a glaucomatous ONH, and be able to look for additional signs that could indicate a glaucomatous ONH.

**Characteristics of the normal ONH (Figure 2)**

The ONH, or optic disc, is a round/oval ‘plug hole’ down which more than a million retinal nerve fibres descend through a sieve-like sheet known as the lamina cribrosa. The retinal nerve fibres are then bundled together behind the eye to form the optic nerve which then continues towards the brain.

The retinal nerve fibres are spread unevenly across the surface of the retina in a thin layer which has a ‘feathery’ appearance, best seen immediately above and below the disc (Figure 3).

As the nerve fibres approach the edge of the disc they pour over the scleral ring (which marks the edge of the disc) and then down its inner surface. The dense packing of nerve fibres just inside the scleral ring is visualised as the neuroretinal rim. The cup is the area central to the neuroretinal rim. The cup edge (where it meets the neuroretinal rim) is best seen by the bend in small and medium-sized blood vessels as they leave, or descend into, the cup.
Most normal discs are more vertically oval and their cup more horizontally oval.

In addition, most (but not all) normal ONHs obey the ‘ISNT’ rule: the Inferior (lower) rim is usually thicker than the Superior (upper) rim, which is thicker than the Nasal rim (inner, nearest the nose). The Temporal rim (outer, nearest the temple) is the thinnest.

Characteristics of a glaucomatous ONH
- Generalised/focal enlargement of the cup. (Note that the cup always appears smaller when viewed monoscopically than in stereo)
- Disc haemorrhage (within one disc diameter of ONH) (Figure 4)
- Thinning of the neuroretinal rim (usually at the superior and inferior poles) (e.g., Figures 5 and 6)

*Continues overleaf*
Figure 6 (left) Glaucomatic optic nerve head of a patient with pseudoxefoliation glaucoma (PXFG). The demarcation of the cup by the blood vessels differs from the margin between the pallor of the base of the cup and the surrounding pinker colour between this and the disc edge. Focussing on the colour difference is misleading. One should judge the edge of the rim by the change in direction of the small and medium-sized vessels which, in this case, indicates a thinner rim than might be suspected by the colour difference.

Figure 7 (below) Glaucomatic optic neuropathy: focal enlargement of cup (notch) and nerve fibre layer defect.

- Asymmetry of cupping between patient’s eyes
- Loss of nerve fibre layer (Figure 7).

Additional signs which should heighten suspicion of a glaucomatous ONH
- Cup/disc ratio (CDR) ≥0.7. A measurement of CDR alone is insufficient and may be misleading as small discs will have smaller cups and hence a smaller CDR. It is important, therefore, to document disc size by measuring the vertical height of the disc. In most populations, only 5% of people with no glaucoma will have a CDR of ≥0.7.
- Rim does not obey the ISNT rule
- Presence of parapapillary atrophy (more common in glaucomatous eyes).

Strategy: distinguishing a glaucomatous ONH from a normal ONH
1. Dilate pupils, if possible and safe to do so.
2. Identify the disc edge and cup edge, and identify the rim.
3. Does the rim thickness obey the ISNT rule?
4. Is there a haemorrhage?
5. Measure the vertical height of the ONH.*
6. Estimate the vertical CDR.
7. Examine the retinal nerve fibre layer (using green light).*
8. Draw an annotated diagram of the ONH.

* This may only be possible with a slit lamp and posterior pole lens. Note that different lenses used at the slit lamp may make the disc seem larger or smaller than it really is. For example, with a 90 dioptre lens the images are magnification is 0.76 (image appears small), so any measurement needs to be divided by 0.76 to be accurate. With a 78 dioptre lens the images magnification is 0.93 and with a 60 dioptre it is 1.15 (image appears large) and with a 66 dioptre lens it is 1.00 (no correction needed).

Is the glaucomatous optic neuropathy worsening or progressing?
The appearance of any of the features of a glaucomatous ONH, or the exacerbation of these features compared to a previous record, is indicative of a progression/worsening of the disease.

Disc haemorrhages may be present for two weeks to three months and are an important prognostic sign of progression. An accurate record requires careful observation and a detailed drawing, and photographic documentation (preferably stereophotography) is highly recommended.

Other imaging devices (see below) assist the clinician in detection of glaucoma when it is unclear from clinical examination whether the optic discs are glaucomatous.

These devices also offer progression analyses to look for structural deterioration, but these are not a surrogate for a detailed clinical examination.

Progressive worsening of the visual fields should correlate with structural changes at the ONH.

Structural imaging of the optic nerve in glaucoma
As part of the clinical assessment of the optic nerve in glaucoma, the International Council of Ophthalmology (ICO) in their Guidelines for Glaucoma Care suggest that structural imaging of the optic nerve may provide a useful but not essential adjunct to direct ophthalmoscopy, slit lamp biomicroscopy and fundus photography when evaluating the optic nerve.

A variety of technologies to analyse the optic nerve are mentioned in the ICO guidelines including confocal scanning laser ophthalmoscopy (Heidelberg Retina Tomograph – HRT), scanning laser polarimetry (GDx Nerve Fibre Analyser – GDx-VCC), and Optical Coherence Tomography (OCT; Figure 8), of which the latter is now the imaging modality of choice. Although structural imaging in isolation using these techniques can differentiate between normal and glaucomatous eyes with mild to moderate visual field loss, none of the current technologies for assessing structural changes of the optic nerve head are suitable for use as an independent screening tool for early to moderate glaucoma or in high risk populations.

Image quality is crucial when assessing structural changes, and it can be difficult to distinguish between glaucomatous structural damage and measurement variability or age-related changes. Furthermore, each technology has its
own optical properties and analysis algorithms and therefore the data acquired is not interchangeable between machines. Monitoring advanced disease can be limited by a floor effect, after which no more thinning is observed. The presence of myopia is also associated with structural thinning of the optic nerve and can confound image interpretation when assessing for glaucomatous progression. These technologies should not replace optic disc photography which remains critically important for the recording of optic disc appearance and subsequent monitoring for change with features such as optic disc haemorrhages not being visible with OCT imaging.

Despite these limitations, structural changes can often precede functional losses and provide an earlier marker of glaucomatous change both in diagnosis and when assessing progression, thus providing useful information during the clinical assessment of the optic nerve in glaucoma.

### Pitfalls and pearls

- The hallmark of glaucomatous optic neuropathy is excavation of the neuroretinal rim.
- Advanced glaucomatous ONH can result in a pale optic disc, but disc pallor should also raise suspicion of another cause such as optic atrophy.
- A colour difference should not be used to distinguish the cup edge; change in direction of the blood vessels is a more reliable indicator (Figure 2).
- The optic disc abnormality should correlate with the visual field defect. Where this is not the case, further investigations, such as imaging of the brains and orbits with MRI or CT, should be considered.
- The size of the cup always appears smaller when viewed microscopically rather than stereoscopically.

**Further reading**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Source</th>
</tr>
</thead>
</table>

Figure 8 Fundus photograph, ocular coherence tomography report and visual field of the right optic nerve of a patient with glaucoma.

a) Fundus photograph

Note the characteristic thinning of the neuroretinal rim and the nerve fibre layer defects whose edges are demarcated by white arrows. There is a diffuse nerve fibre layer defect that involves inferotemporal, inferonasal and nasal regions.

b) Ocular Coherence Tomography report

Note the high quality of the scan, the retinal nerve fibre layer thinning and correspondence of affected peripapillary sectors to what is seen on the photograph and visual field.

c) Visual field of the right eye

Note the dense visual field defect in the superior hemifield that extends to fixation and the small inferior nasal step defect.
Gonioscopy is a technique of viewing the iridocorneal angle: the area between the iris and cornea where the trabecular meshwork is located and where aqueous humour drains out of the eye. Gonioscopy lenses are needed to view the angle, as light from this area would not otherwise reach the observer.

Gonioscopy allows the identification of structures of the anterior chamber angle and an estimation of the angle width; it is also necessary during any procedures affecting the angle, such as laser or surgery.

Anything which impedes drainage through the trabecular meshwork can cause an increase in the intraocular pressure. It is therefore critical that all potential and newly diagnosed glaucoma patients undergo a thorough gonioscopy examination as part of their ophthalmic assessment so that the mechanism of raised intraocular pressure can be established.

In this article, we will focus on a basic gonioscopy technique for the diagnosis of primary and secondary angle-closure glaucoma and for use in angle procedures.

**Structures of the iridocorneal angle**

From anterior (towards the cornea) to posterior (towards the iris), the structures seen are:

1. **Schwalbe’s line.** Demarcates Descemet’s membrane from the anterior trabeculum. It can be located by identifying the corneal wedge (Figure 1).

2. **Non-pigmented trabecular meshwork.** A pale area adjacent to Schwalbe’s line which does not drain aqueous humour.

3. **Pigmented trabecular meshwork.** Brown/pigmented area where aqueous humour drains from the eye; it is critical to identify whether or not it is visible on gonioscopy.

4. **Scleral spur.** A narrow, dense, whitish band posterior to the trabeculum; a consistent landmark in all eyes.

5. **Ciliary body.** A dull, brown band posterior to the scleral spur.

---

Figure 1 Two photographs (A and B) and two drawings (C and D) showing the structures seen on gonioscopy of an open angle. B shows a patient with pigment dispersion where the angle is densely pigmented, especially the pigmented trabecular meshwork. Some patients may have very little pigment present (hypopigmented angle) and identifying the different structures can be challenging. The bottom left image shows a cross-section of the corresponding image on the bottom right. The corneal wedge is shown where the reflections from the inner and outer aspects of the cornea meet, showing the position of Schwalbe’s line, helpful in hypopigmented angles.
Gonioscopy lenses

Direct gonioscopy lenses (Figure 2a), such as the Swan-Jacobs lens, act as prisms and provide a direct, panoramic view of the angle. They are used for surgical procedures on the angle, with the patient lying on their back in the operating theatre.

Indirect gonioscopy lenses (Figure 2b), such as the Goldmann and Magnaview goniolenses (see the panel at the end of the article), combine a prism and a mirror to provide a reflected image of the opposite angle. Gonioscopy is carried out at the slit lamp, with the patient in a sitting position.

Gonioscopy examination technique

Some excellent videos and tutorials are freely accessible at www.gonioscopy.org

- Ensure minimal lighting in the room and a short (1 mm) slit beam to avoid artifactual opening of the angle (bright illumination will cause pupil constriction and opening of the angle).
- Instil topical anaesthesia and explain the procedure to the patient.
- Instruct the patient to keep both eyes open as this results in less squeezing of the eye to be examined.
- For less experienced practitioners, we suggest using an indirect gonioscopy lens with coupling gel as a more stable view is gained.
- Apply a coupling gel to the lens (e.g., carbomer gel).
- Instruct the patient to look up.
- Insert the inferior rim of the lens onto the surface of the eye and then quickly apply the rest of the lens rim to the globe (Figure 3).
- To make insertion easier, the forefinger of the hand inserting the lens can be used to pull the lower lid down and if necessary, the thumb of the other hand to elevate the upper lid.
- Once the lens is in, ask the patient to look straight ahead.
- View the inferior angle through the superior mirror, and vice versa.
- Rotate the lens to view the nasal and temporal angles. In order to best visualise the trabecular meshwork and other angle structures, the slit beam should be at right angles to the mirror and the light offset by 30–60 degrees.

Assessing the angle width and status

First establish whether the angle is open or closed. Iridotrabecular contact (ITC) is present when it is not possible to visualise the pigmented trabecular meshwork without manipulation. A good method of locating trabecular meshwork is to identify Schwalbe’s line (see Figure 1) and then move posteriorly.

“A good method of locating trabecular meshwork is to identify Schwalbe’s line (see Figure 1) and then move posteriorly.”

Continues overleaf

Figure 2a Direct gonioscopy.

Figure 2b Indirect gonioscopy.

Figure 3 Insertion of an indirect gonioscopy lens using coupling gel.
Asking the patient to move the eye in the direction of the mirror, indenting the cornea, or increasing the light can all help to open the angle and visualise more posterior structures. These manoeuvres can help to differentiate between appositional angle closure as compared to synecidal closure. However, grading of the angle width (how open the angle is) should be performed in dim light, with the eye in the primary position and without indentation.

There are a number of different grading systems for angle assessment (see references). In practice, a modified Shaffer grading scheme (Figure 4) is commonly used for grading the angle width. The visibility of angle structures is used:

- **Grade 0.** No angle structures visible.
- **Grade 1.** Schwalbe’s line visible (i.e., the angle is essentially closed as aqueous humour is not able to drain).
- **Grade 2.** Pigmented trabeculum visible (aqueous able to drain but the angle is relatively narrow).
- **Grade 3.** Scleral spur visible.
- **Grade 4.** Ciliary body visible (angle is wide open).

Each quadrant (superior, inferior, nasal and temporal) should be graded. Although this is a quick and easy system it is also helpful to also estimate the angle width in degrees (Figure 5) as it provides more information on risk of future closure.

When assessing whether angle closure is present, or if the patient is at high risk of angle closure, it is important to consider the whole clinical situation (clinical history, symptoms, other examination findings, and so on). For practical purposes, if the angle width is greater than 25 degrees and scleral spur is visible all the way around the angle, there is likely to be a low risk of angle closure. If pigmented trabecular meshwork cannot be seen, i.e., there is iridotrabecular contact for more than two quadrants (over half) of the angle on gonioscopy, there is likely to be a high risk of angle closure. In this situation, intervention to open the angle may be warranted, depending on the presence of other abnormalities such as raised intraocular pressure or risk factors for acute angle closure.

**Indirect gonioscopy lenses**

Goldmann and Magnaview lenses are indirect gonioscopy lenses, or goniolenses (Figure 6), which require the use of a coupling gel to fill the gap between the lens and the cornea and give a stable, undistorted view of the angle structures and configuration. These lenses have either one or two mirrors through which the observer views the angle. The Magnaview lens is larger than all the Goldmann lenses, giving more magnification and allowing a more detailed view of the angle. However, it may be difficult to insert if patients have a small palpebral aperture. It can be used for delivering selective laser trabeculoplasty.

The Zeiss, Posner and Sussman lenses are indirect gonioscopy lenses which allow a rapid view of the entire angle without the need for a coupling gel. They can be used for indentation gonioscopy – pressure is applied on the cornea with the lens, this can help to open up the angle so that further structures can be identified (such as with plateau iris syndrome). If peripheral anterior synechiae are present the angle will not open further even with indentation. The view of the angle is not as stable or clear as that with the Goldmann or Magnaview. Inadvertent indentation can result in corneal striaions and distortion of the view as well as accidental opening up of the angle and misclassification of a closed angle as open.

**Further reading**


University of Iowa Health Care. www.gonioscopy.org

Eyewiki. https://eyewiki.aao.org/gonioscopy
The purpose of glaucoma care is to preserve the quality of life and livelihood of a person with glaucoma, which includes maintaining their visual function while minimising the side-effects and complications of treatment. In order to deliver such patient-centred care, a glaucoma care system which can provide long-term, affordable, sustainable, and equitable care needs to be in place.

The objective of glaucoma treatment

A person with open-angle glaucoma is at risk of irreversible blindness. The objective of treatment is to minimise this risk, usually by lowering the intraocular pressure (IOP) so that an individual upper threshold IOP (also known as their target IOP) is not exceeded. However, we must weigh the expected long-term benefit of preserving vision against side-effects, complications, and the long-term cost of treatment – all of which can affect quality of life and the person’s livelihood.

Choosing a therapy plan

An individual therapy plan is based on a detailed history, visual acuity, and examination of general and glaucoma-related structural and functional details and any changes in these (visual field, disc damage likelihood scale, etc.).

The key result from the history and examination is the rate of progression of the glaucomatous damage. This has to be determined regularly, for each eye separately, and can be divided broadly into three groups:

**Group 1.** Probably no progression, or only a low rate of progression.

**Group 2.** Insufficient information to determine the rate of progression.

**Group 3.** A high rate of progression of vision loss which will probably lead to vision impairment during the patient's lifetime and might have an impact on her or his quality of life and daily activities.

If the rate of progression is low, monitoring can continue, either by only observing the eye or continuing with the same treatment (Group 1). If this was the patient’s first assessment or if there is not enough information from previous examinations available, the risk for progression can be estimated (Group 2). An increased risk of glaucoma progression to visual loss is associated with advanced disease on presentation, high intraocular pressure, older age, certain ethnic groups, disc haemorrhages, and thin central corneal thickness, among others.1,2

If there is an estimated high risk of progression (Group 2), or if there is actual evidence of a high rate of progression (Group 3), an escalation of treatment is indicated. However, it is important to review the current treatment before escalating the therapy;

---

**Key points**

- The aim of patient-centred glaucoma care is to preserve and promote quality of life and livelihood
- The objective of treatment is to minimise the risk of irreversible vision loss
- The individual therapy plan is determined by the rate of progression of glaucoma
- Available treatments should be tailored to the person with glaucoma
- A single measurement of a high intraocular pressure (IOP) alone should not usually trigger a change of the plan
- Refer patients for low vision care, rehabilitation, and counselling as needed.
CHRONIC OPEN-ANGLE GLAUCOMA  Continued

Lowering IOP

Lowering IOP prevents or delays the onset or progression of glaucoma. However, there is no specific IOP threshold, formula, or percentage reduction which applies to all patients. Instead, it is recommended to set and subsequently adapt an individual target IOP. This can be defined as the IOP that slows down the rate of progression of the glaucomatous damage enough to maintain the patient’s quality of life and livelihood during their lifetime.1,3

This definition contains three elements which need to be considered:

• Intraocular pressure
• Rate of progression of the glaucomatous damage
• Quality of life and livelihood.

Analysis of the advanced glaucoma intervention study (AGIS) showed that participants with IOP <18 mmHg at 100% of visits showed no visual field progression.4,5 However, high-quality prospective data comparing different target IOP levels are not currently available; as such, the trade-off between risks and benefits associated with different thresholds is unclear.1 Target pressure should therefore be individualised and may need adjustment over time.1

A single measurement of a high intraocular pressure alone should not trigger a change of management and needs to be put into the context of the other examination results and the history, including self-reported adherence. IOP may also fluctuate within hours or days so that several measurements might provide a better picture of the general level of IOP in an eye. Sometimes a repeat examination on the same day or a repeat follow-up visit within a few weeks might be helpful to decide on the next step, e.g., an escalation of treatment. This also depends on the level of urgency, which can be high for eyes with severe visual field loss and a high rate of progression.

There are several treatment options available to reduce IOP. They can be divided in three groups: medical treatment (usually eye drops but may include oral or intravenous medication, e.g., acetazolamide), laser and surgery. Current cost-effective examples are timolol eye drops, selective laser trabeculoplasty, and trabeculectomy. Other eye drops are only available at considerably higher cost and may not be affordable for some patients in an LMIC context.6

Some examples are given below, but these will vary depending on the local or regional glaucoma care system.

Medical treatment

Medication (a conservative treatment) can reduce IOP by decreasing aqueous production (Table 1a) or enhancing aqueous outflow (Table 1b). Osmotic agents are not mentioned as they are not for long-term use.

<table>
<thead>
<tr>
<th>Laser</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argon laser trabecuoplasty (ALT)</td>
<td>Initial treatment with argon laser trabecuoplasty was at least as efficacious as initial treatment with topical medication (GLT). Risk of scarring of the trabecular meshwork and peripheral anterior synechiae formation.</td>
</tr>
<tr>
<td>Selective laser trabecuoplasty (SLT)</td>
<td>532 nm frequency-doubled Q-switched Nd:YAG laser. Similar efficacy as ALT (LiGHT, KiGIP SLT trials) but less side effects and repeatable.9,10</td>
</tr>
<tr>
<td>Micropulse laser trabecuoplasty (MLT)</td>
<td>Using 810 nm, 532 nm or 577 nm lasers. Possibly similar efficacy as SLT</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Laser</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostaglandin analogues (e.g., latanoprost)</td>
<td>+++(+) Eyelash growth, periorbital fat atrophy, increased iris pigmentation</td>
</tr>
<tr>
<td>Rho-kinase inhibitors (e.g., netarsudil)</td>
<td>++(+) Conjunctival hyperaemia, headache</td>
</tr>
<tr>
<td>Cholinergic agonists (e.g., pilocarpine)</td>
<td>++(+) Headache, dim vision</td>
</tr>
</tbody>
</table>

Laser treatment

Laser treatment can decrease aqueous production by partial destruction of the ciliary body epithelium, which produces aqueous (Table 2a) or by increasing aqueous outflow through the trabecular meshwork (Table 2b).

<table>
<thead>
<tr>
<th>Drug</th>
<th>Efficacy</th>
<th>Side effects (selection)</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-Blockers (e.g., timolol)</td>
<td>+++</td>
<td>Bronchospasm, bradycardia, depression</td>
</tr>
<tr>
<td>Carbonic anhydrase inhibitors (systemic) (e.g., acetazolamide)</td>
<td>++++</td>
<td>Metallic taste, electrolyte imbalance</td>
</tr>
<tr>
<td>Laser Comments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Possibility similar efficacy as SLT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laser Comments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Similar efficacy as ALT (LiGHT, KiGIP SLT trials) but less side effects and repeatable.9,10</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Possibly similar efficacy as SLT | | |

<table>
<thead>
<tr>
<th>Drug</th>
<th>Efficacy</th>
<th>Side effects (selection)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostaglandin analogues (e.g., latanoprost)</td>
<td>+++(+)</td>
<td>Eyelash growth, periorbital fat atrophy, increased iris pigmentation</td>
</tr>
<tr>
<td>Rho-kinase inhibitors (e.g., netarsudil)</td>
<td>++(+)</td>
<td>Conjunctival hyperaemia, headache</td>
</tr>
<tr>
<td>Cholinergic agonists (e.g., pilocarpine)</td>
<td>++(+)</td>
<td>Headache, dim vision</td>
</tr>
</tbody>
</table>

Efficacy and side effects of glaucoma medication to decrease aqueous production

Efficacy and side effects of glaucoma medication to enhance aqueous outflow

• e.g., first checking whether the patient was able to purchase the prescribed eye drops and whether they have actually been taking the treatment.

• Lowering IOP

• Selection of medication

• Referral for laser treatment

• Surgery

• Patient adherence

• Treatment outcomes

Efficacy and side effects of glaucoma medication to enhance aqueous outflow

Efficacy and side effects of glaucoma medication to decrease aqueous production

Efficacy and side effects of glaucoma medication to enhance aqueous outflow

Efficacy and side effects of glaucoma medication to decrease aqueous production

Efficacy and side effects of glaucoma medication to enhance aqueous outflow

Efficacy and side effects of glaucoma medication to decrease aqueous production

Efficacy and side effects of glaucoma medication to enhance aqueous outflow
Surgery
There are several surgical options to reduce intraocular pressure, including a selection of minimally invasive options. ‘Ab externo’ refers to a surgical approach from outside the eye, often involving a conjunctival dissection and scleral incision. ‘Ab interno’ refers to a surgical approach from inside the eye, usually through the anterior chamber, with a corneal incision.

There are three main categories of glaucoma surgery, each with a different purpose:
1. To enhance aqueous outflow into the sub-Tenon space
2. To enhance aqueous outflow through the trabecular meshwork
3. To enhance aqueous outflow through the suprachoroidal space.

1. Surgery to enhance aqueous outflow into the sub-Tenon space

Ab externo approach:
- Trabeculectomy. The gold standard, low-cost procedure to create a guarded fistula between the anterior chamber and sub-Tenon space, requires adherence to follow-up. The Moorfields safer technique (i.e., using releasable sutures), is also suitable in low-resource settings.11
- Glaucoma drainage devices. Aravind Aurolab drainage implants to access the suprachoroidal space (an ab interno approach).
- PreserFlo Microshunt. An aqueous shunt between the anterior chamber and sub-Tenon’s space; drains more posteriorly.

Ab interno approach:
- Goniotomy. Typically used for childhood glaucoma. The trabecular meshwork is incised under direct gonioscopic visualisation using a goniotomy knife (e.g. 25-gauge needle on a syringe).
- Trabeculopectomy. Non-penetrating surgery otherwise similar to trabeculectomy.
- Irridectomy. Improving aqueous flow from the posterior to the anterior chamber.

Ab interno approach:
- iStent. A 360 µm stent with a central lumen of 80 µm implanted into the trabecular meshwork.
- Hydrus. A permanent, 8 mm long, slightly curved microstent to dilate Schlemm’s canal.

2. Surgery to enhance aqueous outflow through the trabecular meshwork

Ab externo approach:
- Canaloplasty. Dilation of Schlemm’s canal using viscoelastic and a suture.
- Trabeculotomy. Accessing Schlemm’s canal via a partial scleral flap. A curved probe (trabeculotome) is rotated gently into the anterior chamber to incise through the trabecular meshwork.
- Deep sclerectomy. Non-penetrating surgery otherwise similar to trabeculectomy.

Ab interno approach:
- STARflo, Gold Micro Shunt. Implants to access the suprachoroidal space (an ab externo approach).
- iStent supra. A 4-mm long curved stent with a lumen of 0.165 mm inserted into the suprachoroidal space (an ab interno approach).

3. Surgery to enhance aqueous outflow through the suprachoroidal space

These include:
- STARflo, Gold Micro Shunt. Implants to access the suprachoroidal space (an ab externo approach).
- iStent supra. A 4-mm long curved stent with a lumen of 0.165 mm inserted into the suprachoroidal space (an ab interno approach).

Focus on the patient, not just the eye
The variety of treatment options available makes it much easier to find an approach to suit the individual patient. There are many factors to consider, including those related to the individual and the health system; see the online version of this article (bit.ly/CEHjpoag) for more detail. It is just as important to ensure that people with glaucoma receive counselling to support their compliance with treatment and quality of life, and to refer them for low vision services and rehabilitation as needed – see the rest of this issue for more information.

Evidence for selective laser trabeculoplasty

The LiGHT trial in the UK10 showed that selective laser trabeculoplasty (SLT) as first-line treatment of ocular hypertension and primary open-angle glaucoma was safe, cost-effective and resulted in the same quality of life (after 3 years) compared to eye drops.

The Kilimanjaro Glaucoma Intervention Programme (KiGIP) SLT trial compared SLT and Timolol eye drops (with standardised counselling) in patients with moderate and advanced glaucoma in Tanzania.11 After one year, SLT treatment was successful in 60.7% of eyes, and Timolol eye drops were successful in 31.3% of eyes. In the SLT group, approximately one third of eyes required one repeat session of SLT; in the Timolol group, a similar proportion needed one repeat session of counselling. Safety, acceptance, vision-related quality of life, and preservation of visual acuity were comparable in both groups after one year. Eye care units in the region using a not-for-profit eye care service model would need to treat around 500 eyes per year with SLT to cover the cost of the procedure, charging an amount similar to one year’s supply of timolol eye drops.

Ab interno approach:
- XEN gel stent. A 6 mm porcine-derived gelatin tube with an inner lumen of 45 µm and outer diameter of 150 µm.

References
How to choose the right treatment for each patient

The variety of treatment options available enables glaucoma care providers to find a treatment, or a combination of treatments, tailored to the person with glaucoma and adjusted to the available glaucoma care in the region.

When choosing the best treatment, or combination of treatments, possible for a glaucoma patient, the many factors we must consider can be usefully grouped into the following areas (see Figure 1):

1. Eye-related factors
2. Person-related factors
3. Treatment-related factors.
4. Health system-related factors

Eye-related factors

Type of glaucoma. Certain types of glaucoma are more aggressive (e.g., exfoliation glaucoma) or might affect central vision faster and require a particularly low target IOP when the rate of progression is high, despite an intraocular pressure in the normal range.

Stage of glaucoma. Consider both eyes, severity of glaucoma can be asymmetric. More advanced disease is at higher risk for progression.

IOP. Baseline IOP and target IOP are important to determine the need for IOP reduction.

Rate of progression. The rate of progression is the most important factor which determines the need for treatment or escalation of treatment. If it is not yet known, there are certain risk factors which can help to estimate the rate of progression.

Comorbidities. Is the eye affected by other conditions, e.g., diabetic retinopathy, trauma, etc.?

Current & previous treatments. Which treatments are currently used? Which eye drops were unsuccessful in the past? How did the patient react to surgery before?

Person-related factors

Age. Chronological and biological age might differ, leading to different decisions. Life expectancy should be considered and depends on several factors, e.g., region, sex.

Preferences. Preferences of a person towards certain treatments can affect adherence.

Health beliefs. Certain (health) beliefs might imply specific behaviour or preferences which can be very important to the patient.

Adherence. What has adherence to follow-up visits and topical treatment been like in the past?

General health. Physical ability to open eye drop bottles and administer eye drops? Side-effects or interactions with other medications or health conditions? Mobility?

Place of living. Determines travel distance, local availability of treatment, e.g., eye drops

Family history. Are other family members affected by glaucoma? Do they need to be examined?

Socio-economic status. Social status: need for assistance? Assistance available at home? Does the family depend on the patient, e.g., for income? Can the treatment be paid for and for how long? Does the patient have health insurance?

Figure 1Four key groups of factors determining the individual treatment tailored to a person with glaucoma. (IOP = intraocular pressure)

Treatment
• IOP lowering effect
  – Mechanism of treatment
  – Access route of treatment
  – Amount
• Acceptance in population
• Side effects
• Safety/complication profile
• Cost

Health system-related factors

Expertise. Level of necessary surgical skills available? Audits or self-audits of outcomes done?

Equipment needed. Laser equipment? Surgical instruments, consumables? Repair and maintenance done regularly?

Availability. Are eye drops available at the place of living of the patient? Consumables for surgery available?

Health insurance. Is health insurance available and could this be recommended to the patient?

Referral network. Is a referral network available? Distance of other facilities? Can follow-up be delegated? Which eye drops are offered?

Treatment-related factors

IOP lowering effect. Is the treatment able to reach the target IOP or below? Duration of the effect?

Acceptance. How likely is it that this type of treatment will be accepted by the patient (and in the target population)?


Complications. Risk of complications? E.g., bleb failure or hypotony?

Cost. Consider initial cost, cumulative long-term cost, follow-up cost (e.g., to treat complications).

Main mode of IOP lowering. Decreasing aqueous production or enhancing aqueous outflow, ab interno or ab externo approach, draining aqueous through trabecular meshwork or sub-Tenon’s.
Counselling in a glaucoma care service

Glaucoma patients often think that their condition is synonymous with blindness and disability, leaving them feeling worried and vulnerable. They may also develop mental health issues such as depression or anxiety. Unfortunately glaucoma patients may have mental health issues even if these concerns are addressed. The glaucoma care team must offer patients balanced information that will help them to understand their options, regain hope for their future, and take practical action to protect their eyes and vision. This support – known as counselling – will help to improve patient’s quality of life.

Who should counsel glaucoma patients?

In a typical, busy clinic, some aspects of counselling can be delivered by examining clinicians, supported by other members of the glaucoma care team. However, it is preferable to give patients access to a dedicated counsellor (who may also offer counselling about other diseases and postoperative care).

Ideally, the glaucoma care team should train someone to take on this role. The person must be approachable, be skilled at talking to patients and their families, and must understand glaucoma and its treatment. Nurses, social welfare, or community health workers could be good candidates for training as glaucoma counsellors.

It is vital that clinical personnel on the glaucoma care team are in close contact with the person responsible for counselling and that they share any relevant clinical information (about the patient) with the counsellor. This enables the counsellor to answer any questions the patients may have, and/or to ask the clinicians for more information if anything is unclear.

The purpose of counselling

Counselling can be helpful in several ways, including:

- To help patients understand their condition and accept their prognosis; this may sometimes include coming to accept that the vision they have lost cannot be restored.
- To find out what patients need or want to do and refer them to other services that may help (e.g. low vision or rehabilitation).
- To provide information and help them make a decision about treatment, such as surgery.
- To improve patients’ compliance with their medical treatment (e.g. regularly instilling eye drops in the correct way).

Focusing on the patient and their needs

A list of information can be helpful and complimentary to counselling and is not necessarily the opposite of counselling. Counselling is, by its nature, patient-centred: the counsellor is focused on the patient, what they know and understand, what they want to do, and what they need in order to have good eye health and to live as well as they possibly can.

Patients’ family members and carers should always be included in counselling and it is important to listen to them. Ask them questions and find out how they intend to help the patient to achieve her or his goals. Another reason for including family members is that suffering from vision impairment or blindness without a visible cause such as a white pupil (as in cataract) can lead to alternative explanations, e.g. laziness or curses, and this can result in the patient being stigmatised by others. Red eyes from eye drops can be mistaken for an alcohol problem, for example. Constant and expensive treatment and visits to the glaucoma care team, seemingly without improvement, may be difficult for the patient to explain.

It may be necessary to provide the same information several times, particularly shortly after diagnosis, when an asymptomatic patient may be in denial. We have to be careful, however, as providing the same information, in the same way, may not have the desired effect – patients may stop listening if the information seems over-familiar. Finding out how patients have used the information in their lives, or how it applies to them, makes for a better approach (see Table 1). Where possible, avoid giving information that sounds like a command. For example, instead of telling a patient to “use your medication or you will go blind”, ask them to tell you what they know about the consequences of not adhering to treatment. Listen carefully, then follow up by asking what they think
they can do to avoid these consequences. After you have listened to the patient, reflect back to them what they have said (“So, what I heard you say is that...”). Then you can explain further or correct any misunderstanding.

**Explaining the disease**

Take care not to overload patients with facts – only give information that they can understand and apply in practice. Start by asking patients what ideas they have about glaucoma and about the subject of the counselling session (e.g., their own prognosis, acceptance of a surgical procedure, or compliance with treatment), and go on from there.

Glaucoma also has a genetic component, and it is important to discuss this carefully and with great sensitivity. Knowing that glaucoma can occur in many family members is helpful as patients can encourage their relatives to come for screening. However, if glaucoma is seen as a condition that will inevitably lead to blindness and disability, there is a risk of stigma which can lead to family difficulties. For example, it could cause problems in a relationship if there are fears about passing the condition on to children. Therefore, the counsellor must be tactful and guide the discussion towards the identification of first-degree relatives, in particular.

**Table 1** Tips for explaining glaucoma to patients: what to ask them, what to tell them (depending on what they have told you), and why it matters.

<table>
<thead>
<tr>
<th>What to ask patients</th>
<th>What to tell them (adapt this depending on what they have told you)</th>
<th>Why this is important</th>
</tr>
</thead>
<tbody>
<tr>
<td>Can you tell me what you know about glaucoma?</td>
<td>Glaucoma typically develops because of increased eye pressure, often because of a reduced outflow from the eye. Reducing the eye pressure can slow down the progression.</td>
<td>When a patient is diagnosed with glaucoma, it often has a negative impact on their quality of life. It is important to explain the causes, how it progresses, and the patient’s individual prognosis so that they are not unnecessarily anxious but will also take any treatment seriously.</td>
</tr>
<tr>
<td>What symptoms made you come to the hospital? Do you know other ways that glaucoma patients can present?</td>
<td>Glaucoma starts very gradually but will get worse over time – it is a progressive disease. In the early stages there may be no symptoms until there is more damage. Vision impairment, which occurs late in the disease, may be the first symptom that brings most people to hospital, but some can recognise a reduction (constriction) in their visual field and come early. Other symptoms may include dullness, aches and pain in the eyes, problems with colour vision, proneness to accidents (from stumbling on objects when walking), haloes (rainbow colours) around point light sources, etc.</td>
<td>Explaining to patients what the symptoms are may help them to educate others, so that people with similar symptoms may be more likely to report it to hospital early. It can also help patients to talk to their relatives and friends about their specific needs, for example the need to remove obstacles at home.</td>
</tr>
<tr>
<td>What do you know about the differences between cataract and glaucoma?</td>
<td>Surgery for cataract (‘white’ blindness) involves replacing the opaque lens (often visible to the patient) with a clear lens, and vision is restored. With glaucoma (‘black blindness’), treatment (including surgery) stops the vision from getting worse. Vision that is lost cannot come back.</td>
<td>Glaucoma and cataract are often confused and facts about cataract might be more widely known in some regions. This article and a poster from a previous edition of this journal, can be used to explain the difference to patients. <a href="http://www.cehjournal.org/article/what-is-wrong-with-my-vision-and-what-can-i-do/">www.cehjournal.org/article/what-is-wrong-with-my-vision-and-what-can-i-do/</a></td>
</tr>
<tr>
<td>What, in your opinion is the aim of treatment for glaucoma?</td>
<td>Treatment of glaucoma does not improve vision and sometimes progression can only be slowed down. But with regular visits and treatment, vision can often be preserved. Follow-up and treatment must be pursued life-long.</td>
<td>Many patients expect an improvement of their vision after treatment. Without explanations, they might assume that the condition is treated with a single bottle of eye drops or may stop if a few months of treatment has not improved their sight.</td>
</tr>
<tr>
<td>Is someone else in your family having a similar problem?</td>
<td>Glauoma may be more common in some families because the disease may be inherited. However, this does not mean that everyone will inevitably have it. This is why it is important for you to advise your first-degree relatives to find time and come to the hospital to check if they have glaucoma. If they come early on, we can treat them before they lose any of their sight.</td>
<td>A positive family history might help the patient to accept the diagnosis and family members can motivate each other to seek counselling and care. Often, a positive family history will help in reducing stigma associated with the disease as other family members have a better understanding of the problem. It also helps the family as a group to reinforce the individual’s management of the disease. It is important to ensure that patients and family members understand what can be done to prevent glaucoma from resulting in vision impairment.</td>
</tr>
<tr>
<td>Do you sometimes see patterns, objects, or people that you know do not exist, or which other people don’t see?</td>
<td>This is known as Charles-Bonnet syndrome, and people who have very advanced glaucoma can be affected. You are seeing these images because of the damage to the nerve at the back of your eyes. You may notice that the images are smaller than you would normally expect; this is typical of the syndrome, and it really is nothing to be concerned about. If you want, I will explain this to your carers and loved ones.</td>
<td>Symptoms of Charles-Bonnet syndrome are caused by cortical stimulation without visual input which leads to visual hallucinations (not auditory, nor olfactory) in people with advanced and end-stage glaucoma. Patients understand that the images are not real and often do not report them because they fear mental illness and possible stigmatisation. The symptoms can also be misinterpreted by those around the patients.</td>
</tr>
</tbody>
</table>

**Top tips**

- Develop a rapport with the person. There should be a relationship of trust – a therapeutic relationship. Listening is vital. Allow the patient to express themselves in their own words. This is also a way of finding out how they understand the situation, and where there may be gaps in their knowledge.
- Explain the disease to them in terms that are easy to understand (see From the Field panel for an example).
- Listen to the patient. Try to understand how they see their disease and its treatment, as well as their interaction with the health system.
- Try and determine what their ‘soft spots’ are – what matters to them? For example, their children, their job, or looking after an older relative? Explaining how adhering to treatment would benefit them and the people or things they care about, may be helpful motivation for them to take action or change their behaviour.
- You may have given them some bad news about vision that is already lost, and which may be lost in future. You must give them time and space to go through the various stages of grief: denial, anger, bargaining, depression and then acceptance. Only when they accept this can they take action.
Encouraging compliance with medical treatment

When discussing eye medication, it is important to ask the patient how often they use their medication and to invite them to demonstrate how they instil it. You can then show them the correct way to do it.

Patients’ ability to instil medication correctly may be affected by several factors, e.g., arthritis of the hands, and it is important to suggest adaptations that can help them, or to train family members to do it for them. Family members can also remind the patient when it’s time to instil their eye medication, which will help to improve their adherence to medication regimes and improve the effectiveness of their treatment.

The PDF of this article (www.cehjournal.org/article/instilling-your-own-eye-drops) can be printed and given to patients as a guide.

Low vision and rehabilitation

If the patient has vision impairment, refer them for low vision services – low vision services can provide equipment and training to help them make the best use of the vision available to them. Patients may also benefit from rehabilitation services, where available, and can learn skills such as reading Braille or using a keyboard, typewriter, or other adaptive technologies.

From the field

How I explain glaucoma to clients

Sani Babayo
Senior Social Welfare Assistant Officer: National Eye Care Centre, Kaduna, Nigeria.

Glaucoma patients are referred to me for counselling by the ophthalmologist. This means that before a patient is referred for counselling, they would have been seen and diagnosed by the ophthalmologist and started on treatment. I call them ‘clients.’ I first of all establish rapport by listening to them and determining where their main concern is. I then correlate the information provided to me by the ophthalmologist.

I start by explaining the eye and intraocular pressure (IOP), vision, and the role of the optic nerve. The optic nerve is within the visual pathway and acts like the wire for a video player. The visual inputs are formed in the brain.

Specifically for glaucoma, I go on to explain the trabecular meshwork and the drainage system for aqueous draining. The analogy is like the gutter system in one’s house – if it is clogged, there is a build-up of water (aqueous). The increase in the amount of water leads to an increase in pressure. In the case of the IOP, it has an effect on the optic nerve. Imagine the optic nerve in rings/layers as an onion. Not all the layers are affected at the same time; the damage starts with the inner layers thereby disrupting the transmission of visual input to the brain. The higher the IOP, the more the layers affected, and the greater the vision loss. This helps the client to understand how the loss of vision happens and where the damage occurs.

I explain that optic nerve damage does not recover. I do not tell them directly that their lost vision will not be recovered. I also try to relate their visual acuity and/or visual field with the level of their cup:disc ratio (indicated by the ophthalmologist). Next, I allow the client to express whether they understand. I watch their expression, ranging from anger to denial and acceptance, depending on their expectations. I note their gestures more than just hearing their words.

I then explain, in detail, their treatment as indicated by the ophthalmologist – the aim of treatment is to maintain the present vision. If they are severely vision-impaired or blind, I talk them through activities of daily living.

“| I allow the client to express whether they understand. I watch their expression, ranging from anger to denial and acceptance, depending on their expectations. |

| “I allow the client to express whether they understand. I watch their expression, ranging from anger to denial and acceptance, depending on their expectations.” |

Sometimes, I make a self-disclosure i.e. by sharing my own story – of what is relevant to them.

The feedback from my patients has been very positive. For example: “Now I understand the disease so I know the relationship between the eyedrops and the rest of my life. I am able to correlate the worsening disease with [problems in] the use of my medication.”

Daily living

A counsellor can also support the patient to adapt to their condition and improve their circumstances. Instead of listing the different environmental modifications they can make, it is better to find about their present condition and how they can adapt, depending on their needs. What do they struggle with, and what do they want to be able to do? For example, finding their way from their home to a friend’s house, or taking care of their physical appearance (personal grooming).

This discussion should be about concrete ideas that the patient can carry out with what they have available. You can make suggestions, but it is also important to elicit from the patient and their family members or carers what they can to achieve that change.

Patients may benefit from joining support groups for people with glaucoma. These are often organised by patients for patients and their relatives, and sometimes they are facilitated by eye care providers such as nurses. Here patients can learn more and share their own experience with others. They can have a positive impact on someone by, for instance, sharing techniques used in maintaining adherence to medication, procurement of medication, or adapting their environment and lifestyle. Find out what groups are available in your area and encourage patients to join them.

Peer mentoring is another useful strategy. This is where the patient is connected to another person with a similar condition to provide guidance towards developing self-help or personal grooming skills, for example.
As a clinician dealing with glaucoma patients, I never had any real formal training in counselling or how to talk to patients. The training most doctors have is to give directives or information to patients, not really knowing whether the patients grasp what we are communicating or not. When patients do not return for follow up, or fail to use their medication as prescribed, we tend to show concern for their health or sometimes even get angry with them for not abiding by our instructions. We get surprised when, despite the severity of the patient’s problems, they fail to adhere to medication or instructions. We talk to patients, give them materials to read but all to no avail. We have the tendency to give too much and often unnecessary information to patients about glaucoma, even when they do not ask for it.

I discovered motivational interviewing during my academic training. Motivational interviewing is an approach to counselling that helps people to make positive changes in their own behaviour to support their health and wellbeing. It involves:

- **Engaging** with the patient and creating a partnership or alliance between the counsellor and the patient.
- **Focusing** on what needs to change – what is the most important target for change? This could be taking medication more regularly, or practicing the correct way to instil eyedrops.
- **Evoking motivation** – working with the patient to find what motivates them to change. Why do they want to make this change? What will be the impact on the things and people that matter to them?
- **Planning** – helping the patient to make concrete plans to make the change and maintain it in future.

Another issue is that many of our patients are used to being directed to do things, so they find it strange that I should ask their view on something or what they intend to do. In many patients there were clear signs of discomfort, as they thought they were being assessed. Their expectation is to be told what to do by us, not the other way round. An elderly woman in the clinic once said to me “Please doctor, stop asking me what I would do. Just tell me what I should do”. Some patients will open up and talk about the eye problem, how it started or presented, what they did, etc., but not what they would do to help themselves. Some don’t want to disappoint you, so they say what they think we want to hear; it becomes a challenge to get them to say what is really going on. They may think that, as their doctor, I will not be happy if they told the truth that they have not been using their medication regularly.

Some patients depend on family members, guardians, or husbands to the extent that they cannot show intent to commit to anything on their own. They lack a sense of agency (feeling able to act on their own behalf) and are not used to having their opinions heard or being involved in making decisions, even about their own health or welfare. With empathy and patience of a trained counsellor, such patients tend to do very well. Furthermore, to avoid “white coat fear”, counselling is better carried out by trained counsellors instead of doctors.

Counselling methods that give positive results should be enhanced and perfected for continued use. The ultimate aim is the welfare of our patients, prevention of blindness, and improvement in their quality of life.

*The author and his colleagues carried out a study to assess the impact of adapted motivational interviewing on acceptance of surgery, adherence to treatment, coming for follow up and ultimately control of intraocular pressure in glaucoma patients.*

**Reference**

People with glaucoma have specific vision-related problems that will affect their daily activities in various ways (Table 1). Learning about patients’ needs and challenges is the first step in offering them useful advice on suitable interventions.

First ask questions (and observe) what your clients need and what they now find difficult when performing their daily activities. Use different tests (clinical and functional) to assess distance and near visual acuity, visual field, contrast sensitivity, and light sensitivity. The CEHJ article ‘When someone has low vision’ lists useful methods.

Check what support there is at home, at work, at school and in the community. This will help you to advise them on training and interventions. For example, if someone needs to be guided at night when walking to the local shop, it would be helpful to train the client and a family member or friend in a safe way of guiding.

Remember to correct presbyopia in older patients before starting other low vision interventions.

### What interventions can help?
Here are some ideas you can suggest to your client.

- Sunglasses can help to reduce the effects of glare and improve contrast. Try a few different coloured lenses to find the ones that work best (see Case study 1, opposite).
- Improve lighting. Consider quantity, type, and direction. E.g., try a reading lamp with a flexible arm in a position that avoids creating glare.
- Ensure enough ambient lighting in dimly lit rooms and prevent large differences in lighting levels.
- Reduce glare by closing curtains or changing position so that you have less excess light.
- Add contrasting strips to steps. Line the borders of the garden with bricks painted white.
- Remove clutter and dispose of little-used items in your kitchen.
- Always carry a torch with you.
- Move closer to the TV.
- Use felt-tipped pens, which are bolder and easier to see.
- Enlarge the labels on your medication or colour code them.
Provide (or advise the client to undergo) compensatory visual field training to enable people with visual field defects to improve navigation and avoid obstacles. For example: “Pause regularly when walking and move your head slowly up and down, then from left to right, to scan the area in front of you. For example, if you scan the area before crossing the street, you may notice a car parked on the street corner which you did not see when looking straight ahead. Then you can avoid bumping into it.”

Refer the client to appropriate peer support groups and to counselling services; these can be of real benefit to them. Other interventions that some (but not all) people need:

• Orientation and mobility training to learn to walk using a white cane, for people who have lost all their vision or have very low visual acuity.
• Magnifiers, after refraction, correction of presbyopia and prescription of glasses has been done (see Case study 2). These can include optical magnifiers (often only low to medium magnification is possible due to the limited visual field) and smartphone apps that magnify. A handheld video magnifier can offer a significantly larger field of view at a given level of magnification and contrast can be enhanced.
• Text-to-speech software, e.g., the free application ‘Non-visual Desktop Access’ (NVDA).
• Reverse telescopes: objects look smaller so that more information fits into a small field of vision (only people with a good distance acuity will benefit).

Case study 1

The client is a 68-year-old woman with glaucoma in both eyes. She has no spectacles and reports problems moving around at night and when the sun shines. She also finds it difficult to see what she is doing when gardening.

Main need identified
Better vision to move around and do her gardening.

Assessment
• She has no spectacles.
• Uncorrected distance visual acuity (VA): 6/60. With a -6.00D correction, VA is 6/36.
• Uncorrected near VA: 2M at 9 cm; best corrected near VA: 1.25M at 10 cm (near add +3.00D).
• Contrast sensitivity: 10%.
• Assessed for magnifier but she does not need it, she says.

Interventions
• Bifocals and cover spectacles (dark glasses that fit over her distance glasses; this reduces glare and too much light)

Client’s comment
“Now I can do my gardening again, and I can do it in comfort.”

Case study 2

The client is a 15-year-old boy with pseudophakic glaucoma in both eyes. He attends primary school and has been on timolol eye drops since infancy.

Assessment
He only has vision in his left eye: uncorrected 6/36 and with spectacles 6/18.

Interventions
Optical magnification (used since 2014):
• Monocular 4x telescope which gives 6/6 distance VA.
• 20.00D (6x) handheld magnifier which gives near VA of 0.8M at 25 cm.

Client’s comments
“Before 2014, even though I had glasses, I still had difficulties in class, e.g., in reading the blackboard and small print in textbooks. Since I was given the telescope and the magnifier, I can read the blackboard without asking for help and all small print.

“These devices make me more confident and my position in class has increased from 65th out of 105 to 14th out of 101 in a school with normally sighted peers.”
Neovascular glaucoma: prevention and treatment

Patients with diabetic retinopathy and retinal vein occlusion are at risk of developing neovascular glaucoma, a blinding and painful condition. Early detection and prompt treatment is vital.

Neovascular glaucoma (NVG) is a devastating type of glaucoma caused when new and abnormal blood vessels block the trabecular meshwork (the tissue that drains fluid out of the eye). The formation of new blood vessels is most frequently caused by diabetic retinopathy (DR) and retinal vein occlusion. However, other atypical causes also need to be considered (see panel).

**Presentation**

In the early stages of this condition, patients present with symptoms of the underlying disease (diabetic retinopathy is the most common cause) such as blurred vision, floaters, or complete vision loss due to a bleed in the back of the eye (retinal or vitreous haemorrhage). As the disease progresses and the intraocular pressure (IOP) increases, patients can develop severe pain in the eye, headache, a red eye, nausea, or vomiting.

On examination, blood vessels can be seen around the pupil (rubeosis iridis); see Figure 1. Large vessels can be detected using a torch, but smaller vessels can be difficult to detect in the early stages, even when using a slit lamp. In order to detect rubeosis iridis early, it is therefore important to **examine the iris before dilation**.

The anterior chamber angle is open in the early stages of neovascular glaucoma. However, as the new vessels grow, peripheral anterior synechiae (adhesions of iris to the cornea) develop and these can close the angle, resulting in further increases in IOP. The pupil also tends to be less reactive to light and eventually progresses to a fixed, dilated pupil with abnormal curling of the more pigmented layer of the iris around the pupil margin (ectropion uveae). The new blood vessels are particularly fragile and sometimes bleed spontaneously in the anterior chamber (hyphema).

**Natural history**

Disease processes in the eye (DR, retinal vein occlusion, or others) trigger the production of vasoproliferative factors such as vascular endothelial growth factor (VEGF), which in turn promotes the formation of new, fragile blood vessels that are prone to leaking or bleeding. The new blood vessels (Figure 1) appear at the pupil margin and/or anterior chamber angle. Initially, the IOP is normal as the new vessels only partially block the angle; not enough to obstruct outflow and increase the IOP. As the vessels continue to grow, aqueous outflow is reduced and the IOP increases, although the angle remains open. Eventually, contractile cells are formed and they cause the iris to adhere to the inner part of the cornea in the periphery of the iris (peripheral anterior synechiae), eventually completely obstructing the trabecular meshwork and inducing ectropion uveae at the pupillary border.

The anatomical blockage of the trabecular meshwork progresses to a complete closure of the angle (the angle is drawn together like a zipper), and the IOP increases to very high levels. As a result, the corneal endothelial cells cannot maintain the cornea’s transparency and corneal oedema appears, visible as a hazy cornea. The breakdown of the blood-aqueous barrier produces anterior chamber flare and inflammation is seen clinically as ciliary injection and anterior chamber cells.

The patient will experience pain, headache, nausea, and vomiting over days to weeks. The pronounced increase in intraocular pressure also damages the optic nerve, with progressive sight loss in the affected eye. In some cases, the ciliary body becomes progressively ischaemic to the point that it no longer produces aqueous humour and some eyes can then progress to phthisis bulbi (a shrunken, non-functioning eye).

In many patients with diabetes, the severity of the neovascular glaucoma may not mirror the severity of the diabetic disease seen on examination of the eye. For instance, many patients with proliferative DR may have normal IOP and no anterior segment neovascularisation. On the other hand, patients with normal visual acuity may have proliferative DR and severe neovascular glaucoma with pain as the first clinical sign that they...
have diabetic eye disease. Therefore, the clinicians who assess patients with diabetes or other retinal vascular diseases should be familiar with neovascular glaucoma and examine patients to assess for neovascularisation of the anterior segment. Patients with neovascular glaucoma should be referred urgently to ophthalmologists trained in treating glaucoma and the underlying retinal causes.

Detection
When examining a patient with, or suspected to have, neovascular glaucoma, ask yourself the following questions.

1. Is the diagnosis neovascular glaucoma, or another type of secondary glaucoma?
2. What is the underlying disease that caused the neovascular glaucoma? The cause is often DR or retinal vein occlusion, but also rule out atypical causes (see panel on p. 10).
3. How high is the IOP? It can be considered severe when the patient develops signs or symptoms of very high IOP (corneal oedema, ocular pain, or headaches).
4. Is the angle opened or closed? See article on gonioscopy within this issue of the journal.
5. What is the visual potential? It can be roughly estimated based on the severity of the macular damage caused by the underlying disease and the damage to the optic nerve caused by glaucoma.
6. What is the life expectancy of the patient?
7. Is the patient in pain or comfortable?
8. Are there underlying systemic diseases that require an urgent referral, such as renal failure or cancer?

Involve the other health care providers who are required to treat the patient (primary care doctor, nephrologist, cardiologist, neurologist, or nutritionist). Advise patients and carers to avoid the overuse of non-steroidal anti-inflammatories (NSAIDs) for pain relief due to the risk of gastrointestinal bleeding.

Treatment
Treatment is challenging and requires close collaboration between different health professionals. Treatment will often involve a combination of medical treatment as well as laser or surgical treatment (see Table 1).

When the angle is still open, early treatment with pan-retinal photoacoagulation and intravitreal anti-VEGF may cause regression of the neovascularisation and a return of IOP to normal. On the contrary, when the angle is closed 360 degrees (zipped), almost all patients will require surgery as their natural outflow cannot be improved. Clinicians should be aware that an intravitreal injection may itself increase the eye pressure. Abrupt reduction of IOP with a paracentesis is not advisable, due to the risk of hyphaema, vitreous haemorrhage, or decompression retinopathy.

Medical treatment
Medical treatment should include steroid, cycloplegic, and IOP-lowering eye drops. Acetazolamide is useful, but it should be prescribed carefully because many patients have renal failure and will be on multiple medications. It should also be avoided in patients with sickle cell disease.

Surgical treatment
The type of surgical management for raised IOP will depend on the visual prognosis and life expectancy. For patients with poor visual potential, an aggressive cyclodestructive procedure with cryootherapy or diode laser can effectively reduce symptoms and partially stabilise the IOP (sometimes it is easier to combine this procedure with peripheral retinal ablation using the same cryotherapy or diode laser).

For patients with good visual potential, an alternative to a cyclodestructive procedure is a glaucoma drainage device, such as an Ahmed or Baerveldt device. The choice of intervention for IOP reduction should consider the presumed life expectancy of the patient and the effects of treatment on the patient’s quality of life, all costs involved (eye drops, surgery, transport, carer availability, time off work), and the patient’s beliefs and preferences.

Blind eyes should only be treated to control pain (see the article on treating the painful blind eye). It should be emphasised that neovascular glaucoma secondary to DR may be asymmetrical, but tends to be bilateral. The treatment of neovascular glaucoma in the worst eye should not distract clinicians from treating the better eye with pan-retinal photoacoagulation.

Table 1 Treatment of neovascular glaucoma according to clinical manifestations

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>IOP</th>
<th>Treatment to control IOP</th>
<th>Treatment to control neovascularization</th>
</tr>
</thead>
<tbody>
<tr>
<td>New blood vessels (rubeosis iridis) on the iris</td>
<td>Normal</td>
<td>No</td>
<td>Pan-retinal photoacoagulation, retinal cryotherapy, or intravitreal anti-VEGF</td>
</tr>
<tr>
<td>or anterior chamber angle</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rubeosis iridis with an open angle</td>
<td>High</td>
<td>IOP-lowering drops, if no improvement surgery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rubeosis iridis with a closed angle</td>
<td>High</td>
<td>Surgery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe neovascular glaucoma (with severe pain or IOP &gt; 40 mmHg at presentation)</td>
<td>Very high</td>
<td>Urgent surgery to lower the IOP, such as a glaucoma drainage device or a cyclodestructive procedure. Intravitreal anti-VEGF, pan-retinal photoacoagulation or retinal cryotherapy will also be needed.</td>
<td></td>
</tr>
<tr>
<td>End-stage (blind) neovascular glaucoma (no perception of light)</td>
<td>Low to very high</td>
<td>Usually for pain control only, e.g., steroids and cycloplegic eye drops, as well as laser or surgery to lower the IOP.</td>
<td></td>
</tr>
</tbody>
</table>
Managing the painful blind eye

Sometimes, despite all efforts to help a patient, visual function is lost permanently and the eye undergoes degenerative changes that can lead to persistent pain. Understanding that vision cannot be restored will help patients to accept suitable treatment.

Figure 1 Neovascular glaucoma often results in a painful blind eye. This eye has a collapsed anterior chamber with angle closure resulting from neovascular glaucoma secondary to proliferative diabetic retinopathy.

Although definitions vary widely, a working definition for a painful blind eye is one with a visual acuity of counting fingers or worse that has no realistic probability of recovering function and is accompanied by ongoing chronic pain and ongoing discomfort which has lasted for at least four weeks.

Causes of the painful, blind eye

A painful, blind eye may result from any disease that causes blindness or a phthisical (shrunken, scarred, and non-functioning) eye. Acute causes include chemical or physical trauma, and chronic conditions include corneal decompensation and advanced and intractable glaucoma, especially neovascular glaucoma.

Understanding eye pain

Mechanical, temperature, irritant and inflammation stimuli in the eye are detected by specialised nerve terminals of the trigeminal nerve (called nociceptors) which send signals to the brain in response to injury or damage in the eye tissues. These nerve terminals are part of the peripheral nervous system, whereas the brain and spinal cord form part of the central nervous system.

The signals are interpreted by the brain as different levels of discomfort, including pain, burning, or stinging, and the response can include increased tearing, blinking, protective movements, and verbal expressions.

There are two types of eye pain:

- **Physiological (normal) pain** resulting from damage to eye tissues. Inflammation (e.g., from uveitis) can also cause increased sensitisation of the nociceptors, resulting in persistent pain that is exaggerated in comparison to any tissue damage.1,2
- **Neuropathic pain** resulting from damage to the nociceptors or the other structures involved in detecting, transmitting and processing pain signals between the peripheral nervous system and the brain. This abnormal signalling response can cause sensations of discomfort and pain in response to non-painful stimuli.1,2

How to manage a painful, blind eye

There are very few evidence-based approaches for managing the painful blind eye. Caregivers should try to differentiate between physiological pain and neuropathic pain, but this can be challenging.

Physiological pain. Pain that responds to anaesthetic eye drops, such as proparacaine hydrochloride, or steroid drops, implies that this is physiological pain originating in the peripheral nerves. Physiological pain can be reduced by treating the underlying cause of the pain and/or by reducing inflammation.

Neuropathic pain. Eyes that don’t respond to anaesthetic drops, or steroid drops in the case of ocular inflammation, suggest a neuropathic type of pain which can be very difficult to treat. Systemic, or even psychological, interventions may be required (ideally via a specialised pain management clinic, although these are not widely available).

Whatever the cause of the pain, the most important management aim is to reduce, or help the patient cope with, the pain. Possible methods of management are outlined below. Alternatives that can be safely performed in the clinical office without the need for a surgical room are classified as “non-invasive” in this article.

Treatment of the underlying cause is important, it is also essential that the patient understands the irreversible loss of visual function; this will help when discussing some of the management options, particularly the more invasive types of treatment.

Continues overleaf
Non-invasive treatments
The first line of treatment usually consists of topical eye drops that may include lubricants, anti-inflammatory drugs (both steroidal and non-steroidal) as well as immunomodulators.

Eye drops containing atropine (a cycloplegic) are commonly used to reduce possible ciliary spasm. A combination of pressure-lowering, steroid, and cycloplegic drops used in the long term can help to reduce pain for patients with a painful blind eye resulting from neovascular glaucoma.

Steroid drops, lubricants and, in some cases, therapeutic contact lenses are useful for patients with corneal issues, for example, a painful blind eye after multiple failed corneal transplants.

Retrobulbar injection of absolute (100%) alcohol to destroy the sensory ciliary nerves has also been used as a pain management option.²

Systemic drugs, including antidepressants and anticonvulsants, can be used for some types of neuropathic corneal pain. These would be given in collaboration with a family doctor or at a pain clinic.

References

Invasive treatment
Where a high intraocular pressure is likely contributing to the pain, trans scleral and endocyclophotocoagulation, high-intensity focused ultrasound (ultrasound cycloplasty),³ and cyclocryotherapy⁴ can be used. Destruction of the ciliary body and reduced aqueous production is the common mechanism of action and they offer the advantage of repeated treatments. Cyclocryotherapy is appropriate where vision has been lost completely.

Where the cause of the pain is a damaged or non-healing corneal surface, procedures such as an amniotic membrane graft or conjunctival advancement (Gunderson) flap will bring relief.

Surgical correction and even implantation of electrode devices have been used for neuropathic ocular surface-related disorders.

Evisceration (removal of the eyeball contents while leaving the sclera, the outer layer of the eyeball behind) and enucleation (complete removal of the eyeball) are the final alternatives that can grant definitive relief.⁴

Conclusion
An understanding of the underlying mechanism, and awareness of the different treatment options, will help direct the best approach for individual patients and achieve sustained pain relief.

Table 1 Summary

<table>
<thead>
<tr>
<th>Common clinical presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Following trauma (e.g., mechanical, chemical, thermal)</td>
</tr>
<tr>
<td>Severe glaucoma, especially neovascular glaucoma (common causes include diabetic retinopathy and retinal vein occlusion)</td>
</tr>
<tr>
<td>Endophthalmitis</td>
</tr>
<tr>
<td>Microbial keratitis</td>
</tr>
<tr>
<td>Uveitis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Non-invasive treatment options</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drops to lower the intraocular pressure (if it is elevated)</td>
</tr>
<tr>
<td>Steroid eye drops</td>
</tr>
<tr>
<td>Oral analgesics including NSAIDs or paracetamol</td>
</tr>
<tr>
<td>Therapeutic (bandage) contact lens for corneal surface damage</td>
</tr>
<tr>
<td>Retrobulbar injection of alcohol or chlorpromazine</td>
</tr>
<tr>
<td>Oral neuropathic pain medication (e.g., amitriptyline or gabapentin)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Invasive treatment options</th>
</tr>
</thead>
<tbody>
<tr>
<td>To lower an elevated intraocular pressure:</td>
</tr>
<tr>
<td>Trans scleral or endocyclophotocoagulation</td>
</tr>
<tr>
<td>Ultrasonic cycloplasty</td>
</tr>
<tr>
<td>Cyclocryotherapy (when vision has been lost completely)</td>
</tr>
<tr>
<td>Corneal protection surgery</td>
</tr>
<tr>
<td>Amniotic membrane graft</td>
</tr>
<tr>
<td>Conjunctival advancement flap</td>
</tr>
<tr>
<td>As a last resort: eye removal</td>
</tr>
<tr>
<td>Evisceration</td>
</tr>
<tr>
<td>Enucleation</td>
</tr>
</tbody>
</table>

Invasive treatment
Where a high intraocular pressure is likely contributing to the pain, trans scleral and endocyclophotocoagulation, high-intensity focused ultrasound (ultrasound cycloplasty),³ and cyclocryotherapy⁴ can be used. Destruction of the ciliary body and reduced aqueous production is the common mechanism of action and they offer the advantage of repeated treatments. Cyclocryotherapy is appropriate where vision has been lost completely.

Where the cause of the pain is a damaged or non-healing corneal surface, procedures such as an amniotic membrane graft or conjunctival advancement (Gunderson) flap will bring relief.

Surgical correction and even implantation of electrode devices have been used for neuropathic ocular surface-related disorders.

Evisceration (removal of the eyeball contents while leaving the sclera, the outer layer of the eyeball behind) and enucleation (complete removal of the eyeball) are the final alternatives that can grant definitive relief.⁴

Conclusion
An understanding of the underlying mechanism, and awareness of the different treatment options, will help direct the best approach for individual patients and achieve sustained pain relief.

Table 1 Summary

<table>
<thead>
<tr>
<th>Common clinical presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Following trauma (e.g., mechanical, chemical, thermal)</td>
</tr>
<tr>
<td>Severe glaucoma, especially neovascular glaucoma (common causes include diabetic retinopathy and retinal vein occlusion)</td>
</tr>
<tr>
<td>Endophthalmitis</td>
</tr>
<tr>
<td>Microbial keratitis</td>
</tr>
<tr>
<td>Uveitis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Non-invasive treatment options</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drops to lower the intraocular pressure (if it is elevated)</td>
</tr>
<tr>
<td>Steroid eye drops</td>
</tr>
<tr>
<td>Oral analgesics including NSAIDs or paracetamol</td>
</tr>
<tr>
<td>Therapeutic (bandage) contact lens for corneal surface damage</td>
</tr>
<tr>
<td>Retrobulbar injection of alcohol or chlorpromazine</td>
</tr>
<tr>
<td>Oral neuropathic pain medication (e.g., amitriptyline or gabapentin)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Invasive treatment options</th>
</tr>
</thead>
<tbody>
<tr>
<td>To lower an elevated intraocular pressure:</td>
</tr>
<tr>
<td>Trans scleral or endocyclophotocoagulation</td>
</tr>
<tr>
<td>Ultrasonic cycloplasty</td>
</tr>
<tr>
<td>Cyclocryotherapy (when vision has been lost completely)</td>
</tr>
<tr>
<td>Corneal protection surgery</td>
</tr>
<tr>
<td>Amniotic membrane graft</td>
</tr>
<tr>
<td>Conjunctival advancement flap</td>
</tr>
<tr>
<td>As a last resort: eye removal</td>
</tr>
<tr>
<td>Evisceration</td>
</tr>
<tr>
<td>Enucleation</td>
</tr>
</tbody>
</table>
Glaucoma is a chronic non-communicable disease. A glaucoma care service can be most effective when it considers every aspect of the care pathway: from educating the patient who did not even know about glaucoma, to the patient receiving treatment and then maintaining compliance with treatment. The authors have previously developed a conceptual framework for the glaucoma care pathway (Figure 1). The conceptual framework for an optimal glaucoma care pathway considers engaging patients in glaucoma care from the community to the hospital and imagines that patients would take certain steps to avoid blindness. It takes into consideration important details about patients’ experiences such as awareness, uptake of health care services, and engaging with their glaucoma care. Understanding the patient’s journey will aid developing improved patient interaction processes that help promote earlier diagnosis as well as uptake of, and compliance with, treatment for glaucoma – with the aim of preventing vision loss and blindness from the disease.

The six stages needed for good glaucoma service delivery are:
1. Raising awareness
2. Access to care and earlier detection of glaucoma
3. Reaching/making a diagnosis
4. Accepting and choosing treatment
5. Compliance with treatment
6. Follow-up and monitoring to detect and treat disease progression.

All of these must be part of an integrated eye care set-up and not delivered in isolation.

Fatima Kyari
Associate Professor: International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK. Consultant Ophthalmologist: College of Health Sciences, University of Abuja, Nigeria.

Rohit C Khanna
Network Director: Allen Foster Eye Health Research Centre & Brien Holden Eye Centre, Gullapalli Pratibha Rao International Centre for Advancement of Rural Eye care, L V Prasad Eye Institute, Hyderabad, India.

**Figure 1 A conceptual framework for the glaucoma care pathway**

<table>
<thead>
<tr>
<th>Natural history</th>
<th>Gradual visual loss and progression to blindness</th>
</tr>
</thead>
<tbody>
<tr>
<td>How people get into the care pathway</td>
<td>What keeps patients in the care pathway</td>
</tr>
<tr>
<td>Poor vision – advanced/severe</td>
<td>Pleasant hospital experience</td>
</tr>
<tr>
<td>Fear of the effect of vision loss</td>
<td>Treatment is explained</td>
</tr>
<tr>
<td>Referred from outreach</td>
<td>Surgery outcomes are explained</td>
</tr>
<tr>
<td>Invited for examination by FDR</td>
<td>Accept treatment</td>
</tr>
<tr>
<td>Unpleasant experience with TEM</td>
<td>Referred to glaucoma patient association (GPA) for information and support with decision making</td>
</tr>
<tr>
<td>Can afford treatment</td>
<td>Maintain follow up</td>
</tr>
<tr>
<td>Adequately monitored</td>
<td></td>
</tr>
</tbody>
</table>

Optimal care pathway: Knowing, access to eye care, accepting treatment, maintaining treatment

Why patients drop out of the care pathway

**Not knowing glaucoma**
- Not knowing the disease
- Not understanding the possibility of further vision loss
- Offered alternate non-medical therapy

**Not reaching a diagnosis**
- Not getting a diagnosis
- Not knowing where to find care
- Far distance from hospital
- Lack of access to information
- Hospitals not adequately equipped
- Late diagnosis

**Not accessing on-going care**
- High cost of care
- Not understanding the treatment
- Unrealistic medical instructions
- Multiple opinions in different hospitals
- Loss of economic productivity

Current situation: Late diagnosis; treatment non-compliance; failed or delayed follow-up

FDR = First-degree relative; TEM = Traditional eye medicine
There is generally poor awareness of glaucoma as a potentially blinding eye condition. Raising awareness among the general public involves a sustained effort to educate the public and boost their knowledge about glaucoma. We suggest providing targeted and appropriate messages via:

- Mass media (e.g., radio, TV, newspapers, information leaflets, magazines, etc.)
- Social media
- Health promotional activities, such as screening for non-communicable diseases
- Special awareness sessions during global events such as World Glaucoma Week or World Sight Day
- Interactive forums, both online and in the community, where patients can learn about their condition and ask questions.

With better health education and awareness, patients can develop the confidence to accept and adhere to treatment.

To improve patients’ access to care, community and primary health care workers can be trained to identify patients with, or at risk of, glaucoma. They should also be involved in increasing awareness among patients and monitoring their compliance with treatment and follow-up. Patients at risk include older adults, first-degree relatives of patients with glaucoma, and people with high intraocular pressure (IOP). It is useful to have a family screening database (or software) to monitor first-degree relatives.

At primary level, a technician can be trained to screen for glaucoma. At the L V Prasad Eye Institute in India, at primary or vision centre level, the Van Herrick test – along with applanation tonometry readings and non-mydriatic images of optic discs – are transmitted to the telemedicine centre for glaucoma detection. Additionally, follow-up care and compliance with therapy are monitored at this level.

The toolkit for glaucoma management in Africa describes the glaucoma care team according to competencies. Depending on their level of competency, members of the eye care team should be able to identify those at risk of vision loss due to glaucoma, provide care for patients with diagnosed and stable glaucoma, initiate treatment, and continue appropriate care for patients with glaucoma in order to prevent vision loss.

Other approaches to earlier detection include systematic population screening and opportunistic case-finding.

Secondary and tertiary eye care facilities should be adequately strengthened to enable them to reach a diagnosis of glaucoma. This requires appropriate equipment, trained, skilled personnel, and good information and management systems. Basic examination includes assessment of the optic nerve head, indentation gonioscopy for anterior chamber angle examination, measurement of central corneal thickness, visual field assessment, and optic disc imaging.

For details of equipment – refer to the IAPB essential list for glaucoma (bit.ly/IAPBglauca) which also categorises the equipment as ‘essential’ or ‘desirable.’

“...To improve patients’ access to care, community and primary health care workers are to be trained to identify patients with, or at risk of, glaucoma.”

Once a diagnosis of glaucoma is made, the patient and care provider are encouraged to ensure that treatment starts as soon as possible and continues for as long as needed. The choice of treatment should be based on the risk that a patient’s vision loss will progress. Consider the following:

- Stage of disease
- Sociodemographic and economic profile of the patient
- Family history of glaucoma or vision loss
- Systemic and ocular co-morbidity.

To enable maintaining treatment and keeping the patient in the care system, the following are important:

- Service responsiveness. This includes a pleasant hospital experience.
- Counselling. Inform the patient about the natural history of the disease, the irreversible vision loss it causes, the available interventions and purpose of treatment, and the need for long-term follow-up (including hospital visits). Cost of care and affordability, opportunity costs and loss of economic productivity should also be discussed.

- Patient participation in their care. The knowledge shared during counselling empowers patients to choose the most appropriate treatment through a shared decision process with the health care provider. Patient forums are also useful to encourage patients’ representation and contribute to how they engage in care. For example, through glaucoma patients’ groups and feedback, they can discuss individual concerns and suggest how the clinic/counselling spaces are organised. Patient groups may also provide peer support, e.g., patients can talk about obtaining medicines and taking them.

Follow-up care is required for monitoring and optimising treatment in response to the progression of the disease. Active mechanisms for contacting patients for follow-up include the use of:

- Clear follow-up instructions and provision of appointment dates
- Keeping patients contact details for texting/calling for reminders
- Glaucoma ambassadors – volunteers within the community who encourage patients in their own care.

References
1 Kyari F, Chandler CI, Martin M, Gilbert CE. So let me find my way, whatever it will cost me, rather than leaving myself in darkness: Experiences of glaucoma in Nigeria. Global Health Action. 2016;9(1).
Minimally invasive glaucoma surgery (MIGS) devices: risks, benefits and suitability

Minimally invasive glaucoma surgery (MIGS) devices can be helpful in managing intraocular pressure in the early stages of glaucoma, thereby reducing patients’ reliance on medication. However, the IOP reduction tends to be small and the devices are expensive.

Minimally invasive glaucoma surgery (MIGS) has emerged in the past few years as a relevant therapeutic option for glaucoma. Intraocular pressure (IOP) reduction is still the only proven treatment to halt glaucoma progression. This has been traditionally achieved by both nonsurgical means (topical medications or laser therapy) and surgical means (trabeculectomy or glaucoma drainage devices). None of these methods are ideal: compliance is the main issue for medications and surgical complications are common. The high safety profile of MIGS allows it to be used earlier than conventional types of glaucoma surgery within a glaucoma treatment plan, and is typically combined with cataract surgery in patients with mild to moderate primary open-angle glaucoma (POAG).

MIGS usually involves the use of a small device that is inserted or placed through a clear corneal incision approached from inside the eye (ab interno). This allows for minimal tissue disruption, a more favorable risk profile, and faster recovery compared to conventional trabeculectomy or glaucoma drainage device implantation (Figure 1).

The benefit is that MIGS tends to be relatively safe and low risk. However, the IOP reduction tends to be small and there is no good evidence for their utility in low- and/or middle-income countries, where patients might be diagnosed with glaucoma at a very advanced stage.

Currently, there are many choices for the glaucoma surgeon where MIGS devices are concerned. They can be divided according to their site of action or placement: Schlemm’s canal, suprachoroidal, and subconjunctival.

1. Schlemm’s canal devices
   - Trabectome, ELT (excimer laser trabeculotomy), iStent, iStent inject, Hydrus, and KDB (Kahook dual blade)

Schlemm’s canal devices are inserted through an ab interno method with the assistance of a gonioscopic lens, aiming to increase aqueous humor outflow through the conventional pathway. Therefore, the potential effect on aqueous outflow is influenced by the resistance provided by the episcleral venous pressure (Figure 2).
The most common procedures include the removal of trabecular tissue (Trabectome, ELT, KDB) or the implantation of a small device (iStent, iStent inject, Hydrus). Among the products currently available, randomised clinical trial data associated the Hydrus with greater eye drop-free glaucoma control and IOP lowering than the iStent; however, these effect sizes were small.3,4

2. Suprachoroidal devices
CyPass and iStent Supra
Unlike the Schlemm’s canal devices, in which aqueous outflow could be affected by episcleral venous pressure, the suprachoroidal space is a potential space that confers minimal resistance to aqueous outflow. It allows aqueous to traverse the sclera directly via the intercellular spaces between ciliary muscle fibres and loose connective tissue of the suprachoroidal space.

At present, there are no suprachoroidal devices clinically available, given that the CyPass MicroStent, despite receiving FDA approval in 2016, was withdrawn from the market after results from a post-marketing study showing accelerated endothelial cells loss.5 The iStent Supra is still undergoing investigation.

3. Subconjunctival devices
XEN-45 and PreserFlo Microshunt
The subconjunctival space, despite not being part of the physiological outflow pathway, is the drainage pathway most familiar to glaucoma surgeons as it is used in conventional glaucoma surgery. Just like the suprachoroidal space, the subconjunctival space is a potential site which is not limited by the episcleral venous pressure; however, aqueous drainage can be compromised by fibrosis and scarring.6

The XEN-45 gel stent is a biocompatible, hydrophilic tube made from porcine gelatin cross-linked with glutaraldehyde. It has been implanted using various techniques (ab-externo/ab-interno, with or without conjunctival peritomy).

The PreserFlo Microshunt is implanted through and ab-externo approach requiring conjunctival dissection. Despite this fact, is has been classified by the FDA as a MIGS device (Figure 3).

Both devices are ‘bleb-forming’: designed to limit or prevent clinically significant postoperative hypotony. On the other hand, this may lead to significant scarring and device failure, the risk of which can be minimised by using antimetabolites and aggressive topical anti-inflammatory therapy in the postoperative period.

“...There are a few key points to bear in mind when considering use of MIGS devices in areas of the world with limited resources for health care. Patients may present with very advanced glaucoma, and MIGS devices are likely to be less effective in these group of patients. Also, trials to date have been limited to patients with early to moderate disease.

Conventional glaucoma surgery is still the gold standard for surgical management of glaucoma, and no MIGS device has been compared head-to-head with trabeculectomy or aqueous shunt in a randomised controlled trial.

Finally, MIGS devices are relatively expensive and therefore less likely to be a practical option in countries with limited resources. Some glaucoma drainage devices cost as little as US $50, compared to US $400 or more for any MIGS device; this also doesn’t take into account the extra cost of surgical goniolenses or the steep learning curve/training required for this type of surgery.

More prospective randomised trials, with longer follow-up periods, are required to further evaluate the efficacy and safety of this rapidly evolving field of glaucoma treatment. Further comparative studies between devices would also be helpful to evaluate their relative efficacy.

References
The global challenge of glaucoma

Glaucoma is a major cause of irreversible blindness worldwide. It also results in substantial disability, even before people become blind from it, but remains undertreated globally. In most surveys carried out in high-income countries, over 50% of people found to have glaucoma had not been diagnosed and are therefore not receiving treatment. In low-income and/or middle-income countries (LMICs), this rises to over 90%. This high percentage is because glaucoma is mostly asymptomatic until relatively late in the disease. In LMICs, as many as 35% of people diagnosed with glaucoma are already blind as a result – it is too late for them to benefit from effective interventions that would have prevented vision loss.

Whereas cataract has a one-stop solution (cataract surgery), glaucoma requires more complex management strategies because of its chronic nature and complexity. In the absence of simple and affordable diagnostic and treatment solutions, the global eye health community has not prioritised glaucoma; for example, when VISION 2020 was being developed more than 20 years ago. There are several crucial issues.

First, there is a need to provide effective treatments that prevent glaucoma progression and, maybe someday, restore visual function to those with glaucomatous damage. Lowering intraocular pressure (IOP) slows, and in some cases stops, glaucoma progression, but doing so safely and effectively remains a challenge. The current treatment is often long-term topical eye drops, but poor compliance and ongoing costs are major challenges in low-resource settings. Laser trabeculoplasty, which can be administered in a single session, is an effective strategy that has shown effectiveness in such settings. Unfortunately, it rarely provides lifetime control of IOP. Although there is hope that in the future more effective surgical or laser approaches will provide safe and sustained pressure lowering, more work needs to be done.

Second, individuals need to be monitored to determine whether their glaucoma is progressing so that treatment can be adjusted as needed. Monitoring presents challenges for more remote and resource-limited populations, but home-based monitoring using off-the-shelf technology might become available in the near future. The growth of vision centres in India and elsewhere, staffed by mid-level ophthalmic personnel and supported remotely by ophthalmologists, is an example of how to provide ongoing monitoring and care for people living in remote settings.

Third, affordable and effective screening approaches are needed to enable identification of individuals at risk of sight loss. Major advances in the automated grading of optic disc photographs have led to highly accurate glaucoma diagnoses on the basis of a single photo. Widespread use of screening using fundus imaging, with artificial intelligence-assisted grading, could allow glaucoma to be diagnosed alongside the other major causes of blindness at low cost. Implementation studies are needed to determine how and where to apply these new tools.

Innovation in glaucoma detection and management could catalyse a new care model in which earlier detection and effective long-term IOP lowering, combined with remote monitoring, can prevent unnecessary blindness worldwide. To reach this goal, the global eye care community must include glaucoma in eye care planning, recognising that the patient is a central partner in its management. Many important research questions remain unresolved and require substantial investment and a concerted global effort to answer.

The Lancet Global Health Commission on Global Eye Health, a wide-ranging report synthesising new and existing research across many aspects of eye health, looked at the global challenges of offering glaucoma care to everyone who needs it.
Exploring strategies for trachoma elimination in Ethiopia

Human resources for trachoma elimination remain a challenge in the remote communities of Ethiopia.

Ethiopia has the greatest burden of trachoma worldwide, accounting for 49% of 136.2 million people at risk globally.1 In 2021, the World Health Organization (WHO) reported that almost 460,000 people in Ethiopia require surgery to treat trachomatous trichiasis (TT), the late blinding stage of the disease.1

Although the Ethiopian Federal Ministry of Health has made significant progress in scaling up all components of the WHO-endorsed SAFE strategy (surgery, antibiotics, facial cleanliness, and environmental improvement), efforts to reduce the TT backlog are complicated by the remoteness of the communities affected by the disease, limited access to health services, and inadequate human resources for eye health to provide standardised TT surgery training and high quality treatment.

To maximise the impact of its national trachoma programme, the Ethiopian Federal Ministry of Health has implemented two human resource strategies across eye health services and the trachoma programme to progress towards trachoma elimination targets. One strategy trains general health workers, and the other trains allied eye health workers.

1. General health workers

In several parts of the country, including the regions of Amhara, Oromia, and SNNP, the backlog is being addressed by the training, certification, and supervision of general health workers, including general nurses, to identify and manage TT, including by providing TT surgery. In Ethiopia, this group of health workers is known as integrated eye care workers (IECWs); they work at the primary health care level.

This model requires the empowerment of local authorities to provide supervision as well as technical and administrative support. By upskilling existing human resources, it has been successful in scaling up case-finding and management of TT in the regions where it is being implemented.

However, several challenges remain. As TT cases decline, the quality of surgery becomes difficult to maintain since IECWs conduct fewer operations and thereby have less opportunity to practise their skills. It has also been observed that IECWs have much higher rates of turnover due to the lack of career pathways and limited incentives. This can increase the costs of training and have a negative impact on the quality of care.2

2. Allied eye health workers

An alternative strategy is being used in the region of Tigray, where allied eye health workers (ophthalmic nurses, ophthalmic officers, and cataract surgeons) are trained and deployed to clear the TT backlog in the region. Ethiopia’s national trachoma programme trains and certifies these allied eye health workers to carry out TT surgery as per the WHO Trichiasis surgery for trachoma manual (bit.ly/TT-surgery).

Upskilling ophthalmic nurses and ophthalmic officers has several benefits. First, during TT surgery campaigns, the use of specialist eye care workers means patients with other eye conditions can be treated or referred to secondary level eye care units when diagnosed with conditions such as cataract or glaucoma. The use of allied eye health workers therefore better facilitates the transition of the trachoma programme into the existing eye health system. This helps to ensure high quality of care and improves trust in services.

References

The Trachoma Update series is kindly sponsored by the International Coalition for Trachoma Control www.trachomacoalition.org

© [Image] ORBIS CC BY-NC 4.0
Test your knowledge: glaucoma

Test your own understanding of the concepts covered in this issue and reflect on what you have learnt.

We hope that you will also discuss the questions with your colleagues and other members of the eye care team, perhaps in a journal club. To view the activities online, please visit: www.cehjournal.org

Tick ALL that are TRUE

**Question 1**
Detecting and diagnosing glaucoma, including optic nerve head examination and gonioscopy?

- [ ] a. Optical coherence tomography (OCT) is essential for making a definite (unequivocal) diagnosis of glaucoma.
- [ ] b. Gonioscopy is an optional part of the examination of glaucoma patients.
- [ ] c. Loss of the superior part of the visual field (such as an arcuate scotoma) from glaucoma would usually be associated with thinning/notching of the superior part of the optic disc.
- [ ] d. Many patients with glaucoma are asymptomatic and may present with irreversible vision loss in one eye.

**Question 2**
Neovascular glaucoma and managing the painful blind eye

- [ ] a. Treatment for a painful blind eye due to neovascular glaucoma may include injection of 100% alcohol into the eye to destroy the sensory ciliary nerves.
- [ ] b. Non-invasive treatment options for a painful, blind eye may include atropine eye drops, steroid eye drops, and oral analgesics such as paracetamol.
- [ ] c. The most common causes of neovascular glaucoma are diabetic retinopathy and retinal vein occlusions.
- [ ] d. Severe neovascular glaucoma is an urgent/emergency eye condition any may require intravitreal injection, pan-retinal photocoagulation (PRP) laser, and glaucoma surgery.

**Question 3**
Managing chronic open-angle glaucoma and running a glaucoma programme

- [ ] a. All glaucoma patients require treatment which may include drops, laser, or surgery.
- [ ] b. The purpose of glaucoma care is to preserve the quality of life and livelihood of a person with glaucoma, which includes maintaining their visual function while minimising the side-effects and complications of treatment.
- [ ] c. Minimally invasive glaucoma surgery is safe and effective at reducing intraocular pressure and is replacing more conventional types of glaucoma surgery (for example trabeculectomy).
- [ ] d. Selective laser trabeculoplasty has good evidence for its use to treat glaucoma in low- and high-income settings.

**ANSWERS**

1. a. False. Glaucoma is diagnosed by observing changes to the optic disc that correspond to visual field defects. OCT is not essential.
   - b. False. It is vital to identify whether there is irido-trabecular contact or angle closure in patients with glaucoma and to treat this appropriately.
   - c. False. A superior visual field defect would usually be associated with thinning/notching of the inferior part of the optic disc, and vice versa.
   - d. True. Treatment should prevent further vision loss in that eye and the other eye if it is also affected.

2. a. False. Retrobulbar (behind the eye) injection of alcohol may be used.
   - b. True.
   - c. True.
   - d. True.

3. a. False. Not all glaucoma patients require treatment; for example, a patient with slowly progressive disease and a short life expectancy whose quality of life will not be affected by the glaucoma.
   - b. True.
   - c. False. The evidence for MIGS is limited, especially in low- and middle-income settings, and they tend to give a relatively small reduction in intraocular pressure.
   - d. True. The LiGHT study in the UK and the KiGIP study in Tanzania showed it was safe and effective compared to eye drops for open-angle glaucoma.
PICTURE QUIZ

A 75-year-old woman presents with painless blurring of vision in the right eye for the last few months. The visual acuity is 6/60 in that eye. The photograph shows the optic disc.

Select ALL that are TRUE

Question 1
The following features can be seen in the optic disc photo

- a. Swelling of the optic disc
- b. An extremely thin optic disc rim
- c. Parapapillary atrophy
- d. Nasal displacement of the central retinal vessels

Question 2
Characteristics of glaucomatous optic disc include:

- a. Disc haemorrhages
- b. Thinning of the optic disc rim, usually nasally
- c. Generalised/focal enlargement of the cup

Question 3
Appropriate next steps in this patient would include:

- a. A full ocular examination of both eyes including visual acuity (individual eyes), intraocular pressure measurements, examining the optic disc in the other eye and looking for secondary causes of glaucoma, such as uveitis or trauma
- b. Discharging the patient if both eyes have poor vision from advanced glaucoma as nothing more can be done
- c. Advising family members to be screened for glaucoma

ANSWERS

1. Answer: b, c and d. There is no optic disc swelling. This disc shows advanced glaucomatous damage.

2. a and c. Thinning of the optic disc rim is characteristic of glaucoma, but this usually occurs at the superior and inferior poles (see article “The optic nerve head in glaucoma”).

3. a and c. It is very important to do a full examination of both eyes. If the intraocular pressures are high they should be treated urgently. It is very important to stop further glaucomatous damage and vision loss. If patients have already developed vision loss due to glaucoma they should be given appropriate advice and support including referral to peer support groups, counselling services and access to low vision aids. Family members of glaucoma patients should be screened for glaucoma; this can be done by optometrists in some settings.

USEFUL RESOURCES

GLO A Guide
Glaucoma UK (previously the International Glaucoma Society) has published a range of very useful patient information leaflets which are available as free PDF downloads. https://glaucoma.uk/

Webinar – save the date!
Join us for the Community Eye Health Journal Glaucoma Webinar on World Glaucoma Day: 10 March 2022, 1–2 pm GMT (UK time). We will be speaking the authors whose articles feature in this issue and there will be time for questions and feedback from our readers. Sign up for our newsletter to receive the Zoom link nearer the date. Visit www.cehjournal.org/subscribe/

Patient information

Guidelines

The European Glaucoma Society guidelines
The most recent edition can be accessed at www.eugs.org/eng/guidelines.asp (accessed 1 June 2021)

www.aao.org/preferred-practice-pattern/

www.aao.org/preferred-practice-pattern/

Previous articles from the Community Eye Health Journal

How to assess a patient for glaucoma
www.cehjournal.org/article/how-to-assess-a-patient-for-glaucoma/

Visual field testing for glaucoma – a practical guide
www.cehjournal.org/article/visual-field-testing-for-glaucoma-a-practical-guide/

Emergency management: angle-closure glaucoma
www.cehjournal.org/article/emergency-management-angle-closure-glaucoma/

Managing a patient with open-angle glaucoma: a case study

Primary open-angle glaucoma: everyone’s business
www.cehjournal.org/article/primary-open-angle-glaucoma-everyones-business/

‘An ideal service for glaucoma would be…’
www.cehjournal.org/article/an-ideal-service-for-glaucoma-would-be/

Patients and glaucoma: what are the challenges?
www.cehjournal.org/article/patients-and-glaucoma-what-are-the-challenges/

Conversations with glaucoma patients
www.cehjournal.org/article/conversations-with-glaucoma-patients/

© RUPERT BOURNE CC BY-NC 4.0